药明巨诺
JW Therapeutics

JW (Cayman) Therapeutics Co. Ltd

藥明巨諾(開曼)有限公司*

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 2126

INTERIM REPORT
2025

* For identification purpose only

Contents

Corporate Information

BOARD OF DIRECTORS

Executive Director

Mr. Min Liu (劉敏) *(Chairman)*[1]

Non-executive Directors

Dr. Yiping James Li *(Chairman)*[2]
Ms. Xing Gao (高星)
Dr. Sungwon Song
Dr. Cheng Liu

Independent Non-executive Directors

Mr. Kin Cheong Kelvin Ho (何建昌)
Dr. Debra Yu
Mr. Peng Kuan Chan (陳炳鈞)

AUDIT COMMITTEE

Mr. Kin Cheong Kelvin Ho (何建昌) *(Chairman)*
Ms. Xing Gao (高星)
Mr. Peng Kuan Chan (陳炳鈞)

REMUNERATION COMMITTEE

Dr. Debra Yu *(Chairperson)*
Dr. Sungwon Song
Mr. Peng Kuan Chan (陳炳鈞)

NOMINATION COMMITTEE

Mr. Kin Cheong Kelvin Ho (何建昌) *(Chairman)*
Mr. Min Liu (劉敏)
Dr. Debra Yu

BUSINESS DEVELOPMENT AND STRATEGY COMMITTEE

Dr. Debra Yu *(Chairperson)*
Mr. Min Liu (劉敏)
Ms. Xing Gao (高星)

COMPANY SECRETARY

Ms. Ka Man Ng (吳嘉雯)

AUTHORIZED REPRESENTATIVES

Mr. Min Liu (劉敏)
Ms. Ka Man Ng (吳嘉雯)

HONG KONG LEGAL ADVISORS

Fangda Partners
26/F, One Exchange Square
8 Connaught Place
Central
Hong Kong

1. Mr. Min Liu has been appointed as Chairman, with effect from March 13, 2025.
2. Dr. Yiping James Li has stepped down as Chairman with effect from March 13, 2025.

REGISTERED OFFICE

The offices of Maples Corporate Services Limited
PO Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands

HEADQUARTERS IN THE PRC

5F, Building B
No. 699 Zhong Ke Road
Pudong New District, Shanghai
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

31/F, Tower Two, Times Square
1 Matheson Street, Causeway Bay
Hong Kong

PRINCIPAL SHARE REGISTRAR

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall, Cricket Square
Grand Cayman, KY1-1102
Cayman Islands

HONG KONG SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712–1716
17th Floor Hopewell Centre
183 Queen's Road East, Wanchai
Hong Kong

PRINCIPAL BANKER

China Construction Bank
Shanghai Free Trade Zone Branch
No. 17 Jiafeng Road
Shanghai
PRC

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditor
35/F, One Pacific Place
88 Queensway
Admiralty
Hong Kong

STOCK CODE

2126

COMPANY'S WEBSITE

www.jwtherapeutics.com

Financial Highlights

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**106,346**	86,815
Cost of sales	**(41,229)**	(43,070)
Gross profit	**65,117**	43,745
Other income	**4,282**	1,884
Other gains and losses	**(160,116)**	(6,729)
Selling expenses	**(58,494)**	(76,172)
General and administrative expenses	**(32,190)**	(59,233)
Research and development expenses	**(92,041)**	(151,008)
Finance income	**12,423**	13,299
Finance costs	**(6,246)**	(6,053)
Finance costs — net	**6,177**	7,246
Loss before tax	**(267,265)**	(240,267)
Income tax expense	**—**	—
Loss for the period	**(267,265)**	(240,267)
Other comprehensive (expense) income		
Items that will not be reclassified to profit or loss:		
Exchange differences arising on translation from functional currency to presentation currency	**(1,158)**	15,829
Items that may be reclassified subsequently to profit or loss:		
Exchange differences arising on translation of foreign operations	**3,228**	3,719
Other comprehensive income for the period	**2,070**	19,548
Total comprehensive expense for the period	**(265,195)**	(220,719)
Non-IFRS measure:		
Adjusted loss for the period	**(103,327)**	(214,712)

- **Revenue** amounted to RMB106.3 million for the six months ended June 30, 2025, representing an increase of 22.5% compared to RMB86.8 million for the six months ended June 30, 2024. Revenue was generated from (i) sales of Carteyva®, our product currently under commercialization; and (ii) a non-exclusive license granted to Juno under the JW sLVV Manufacturing Process and related know-how (including patents).

- **Gross profit** was RMB65.1 million for the six months ended June 30, 2025, representing an increase of 48.9% from RMB43.7 million for the six months ended June 30, 2024, primarily driven by the incremental contribution from the grants of sLVV license. Gross profit margin of product sales was 51.1% for the six months ended June 30, 2025, representing an increase from 50.4% for the six months ended June 30, 2024. The Company devoted continuous efforts in enhancing the efficiency of manufacturing operations, exploring new technologies for process improvement and implementing our cost reduction plans.

- **Selling expenses** were RMB58.5 million, accounting for 72.0% of product revenue for the six months ended 30 June 2025, compared with RMB76.2 million, or 87.7% of product revenue for the six months ended 30 June 2024. The improvement was primarily attributable to the execution of the Group's optimization strategies in relation to its commercial initiatives, coupled with the implementation of its organization effectiveness program. We successfully delivered on our commercialization strategy and expanded our coverage while streamlining costs in the first half of the year.

- **General and administrative expenses** amounted to RMB32.2 million for the six months ended June 30, 2025, representing a decrease of 45.7% from RMB59.2 million for the six months ended June 30, 2024, primarily attributable to the streamlined organization and continuous operational excellence leading to a decrease in labor cost and professional service fees.

- **Research and development ("R&D") expenses** amounted to RMB92.0 million for the six months ended June 30, 2025, representing a decrease of 39.0% from RMB151.0 million for the six months ended June 30, 2024, primarily attributable to an enhanced operation efficiency and optimized R&D strategy including: (i) optimization of the Group's R&D workforce; (ii) a decrease in R&D materials; and (iii) a decrease in testing and clinical fees.

- **Other gains and losses** amounted to RMB160.1 million for the six months ended June 30, 2025, as compared to RMB6.7 million for the six months ended June 30, 2024. This increase was primarily attributable to the recognition of impairment of license amounting to RMB152.6 million that was related to product JWATM204/214 based on an adjustment noted in the valuation report prepared by an independent valuer, which took into account a variety of factors including the level of complexity of R&D pathways, the time and resources that might be required in advancing in-depth analysis with clinical data, and the overall R&D investment efforts required to work toward commercialization. The Company estimated that these factors may affect the revenue growth, which gave rise to the recognition of impairment loss.

- **Loss for the period** was RMB267.3 million for the six months ended June 30, 2025, as compared to RMB240.3 million for the six months ended June 30, 2024. The increase was mainly due to a RMB152.6 million provision for impairment of the license related to product JWATM204/214, reflecting an adjustment in the independent valuation report. Encouragingly, our recurring operating loss was RMB114.0 million for the six months ended June 30, 2025, representing a decrease of RMB126.5 million from RMB240.5 million for the six months ended June 30, 2024, which was primarily attributable to: (i) increased total revenue and gross profit generated from sales of Carteyva® and grant of a license; (ii) decreased general and administrative expenses due to streamlined organization and control on professional service fees; (iii) decreased selling expenses resulting from the Group's optimization strategies in relation to its commercial initiatives and commercial workforce; and (iv) decreased R&D expenses attributable to workforce optimization and a decrease in expenses relating to R&D materials, testing and clinical fees.

- **Bank balances and cash** amounted to RMB646.9 million as at June 30, 2025, representing a net cash outflow of RMB110.5 million for the six months ended June 30, 2025 compared to RMB136.9 million for the six months ended June 30, 2024.

NON-IFRS MEASURE

To supplement the Group's consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted loss[1] for the period as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that these adjusted measures provide useful information to Shareholders and potential investors in understanding and evaluating our consolidated results of operations in the same manner as they help our management.

Adjusted loss[1] was RMB103.3 million for the six months ended June 30, 2025, representing a decrease of RMB111.4 million from RMB214.7 million for the six months ended June 30, 2024. The reduction in loss was primarily attributable to (i) increased total revenue and gross profit generated from sales of Carteyva® and grant of a license; (ii) decreased general and administrative expenses due to streamlined organization and control on professional service fees; (iii) decreased selling expenses resulting from the Group's optimization strategies in relation to its commercial initiatives and commercial workforce; and (iv) decreased R&D expenses attributable to workforce optimization and a decrease in expenses relating to R&D materials, testing and clinical fees.

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(267,265)**	(240,267)
Added:		
Share-based compensation expenses	**4,536**	18,557
Impairment of license	**152,602**	—
Net foreign exchange losses	**6,800**	6,998
Adjusted loss for the period (Non-IFRS)	**(103,327)**	(214,712)

[1] Adjusted loss for the period is not a financial measure defined under IFRS. It represents the loss for the period excluding the effect of the following non-cash items: (a) share-based compensation expenses; (b) impairment of license; and (c) net foreign exchange losses. It is intended to be used as a supplement to the Group's interim results prepared in accordance with IFRS and is not intended to be considered in isolation or as a substitute for IFRS net loss for the period. For the calculation and reconciliation of this non-IFRS measure, please refer to "Management Discussion and Analysis — Financial Review — 11. Non-IFRS Measure" in this interim report.

For the six months ended June 30, 2025, and as of the date of this report, as an independent, innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products, we have made significant further progress in our business, achieved important milestones, and comprehensively enhanced operation efficiency, such as the stable gross profit margin, expanded marketing initiatives with efficient control on selling expenses, streamlined organization and reduced net cash outflow. Our lead product, Carteyva®, continued to make progress in its commercialization. Additionally, we have completed patient enrollment in clinical trial with Carteyva® as second-line therapy for transplant-ineligible patients with relapsed or refractory ("**r/r**") Large B-Cell Lymphoma ("**LBCL**"). The NMPA granted Breakthrough Therapy Designation to Carteyva® for this indication in January 2025, and we submitted a supplemental New Drug Application ("**sNDA**") for it in May 2025. In addition, we have developed our platform process and successfully manufactured lentiviral vectors to produce Carteyva®, further reducing product costs. Analytical and clinical studies have shown comparable results to those of the current lentiviral vectors. Currently, we have completed patient enrollment for the investigational new drug ("**IND**") study of these vectors. Moreover, we have made significant progress in developing innovative products with global commercialization potential.

Since the beginning of 2025, we have achieved the following significant milestones in our business:

Commercialization

- We continued to execute our cost reduction plans in 2025, which enabled us to further reduce manufacturing costs of sales per batch and to maintain a relatively stable gross profit margin of 51.1% for product sales for the six months ended June 30, 2025.

- For the six months ended June 30, 2025, Carteyva® has been listed in more than 90 commercial insurance products and 104 local governmental complementary medical insurance programs.

- We enhanced our commercialization strategy, improved efficiency, and expanded our coverage to drive our sales revenue.

Research and Development

Hematologic malignancies

- Regarding our Phase II registrational clinical trial for Carteyva® as a second-line therapy for transplant-ineligible patients with r/r LBCL, we completed patient enrollment in the second half of 2024. The NMPA granted Breakthrough Therapy Designation to Carteyva® for this indication in January 2025, the primary endpoint was met, and we submitted an sNDA for this indication in May 2025.

- In the second half of 2024, we announced the commencement of a first-in-human investigator-initiated trial ("**IIT**") study relating to JWCAR201 (dual CAR-T targeting CD19/20), focusing on hematologic malignancies. Patient enrollment in this study is currently ongoing, and the preliminary data are promising.

Autoimmune diseases

- With respect to the ongoing IIT relating to relma-cel as a treatment for systemic lupus erythematosus ("**SLE**"), initial trial data were reported at the 2024 European Alliance of Associations for Rheumatology Congress. With long-term follow-up, the durable and deep response was observed, and further publication is planned.

- Based on the promising preliminary results of the IIT study, we commenced a phase I clinical trial of relma-cel as a treatment for SLE in May 2024. In the first quarter of 2025, patient enrollment was completed.

- In late 2024, we announced the commencement of a first-in-human IIT study relating to JWCAR201 (dual CAR-T targeting CD19/20), focusing on autoimmune diseases, and patient enrollment in this study is currently ongoing.

Solid tumors

- Starting from the first half of 2024, we commenced clinical development of cell therapy products directed to melanoma-associated antigen A4 ("**MAGE-A4**"), based on the rights that we in-licensed from 2seventy bio, Inc. ("**2seventy bio**") in the second half of 2022. 2seventy bio's oncology and autoimmune research and development programs were subsequently acquired by Regeneron Pharmaceuticals Inc. ("**Regeneron**"). With the scientific expertise of Regeneron and Juno in cell therapy, we anticipate that the combination with the Company's own expertise will enable us to further advance our R&D capabilities. We have established our manufacturing process for a product directed to MAGE-A4, and patient enrollment in an IIT was initiated in the first quarter of 2024. Currently, this study is currently in the dose-escalation phase of patient enrollment.

Discovery and Early Research

Our early research and development efforts focus on innovative pipeline products, leveraging our established infrastructure and expertise. The Company aims to expand internationally without regional restrictions. The new pipeline targets hematological cancers, solid tumors, and autoimmune diseases, with "Armor" elements designed in-house to enhance the CAR therapies' efficacy and durability. One of our first in-house developed products is JWCAR201, a dual targeting CD19/20 autologous CAR-T cell therapy designed for B-cell malignancies and autoimmune diseases, which is expected to have a broader range of effectiveness, increased signaling threshold, and significantly reduced risk of relapse due to antigen downregulation or loss which is commonly observed in hematological cancers. Another two new CAR products for solid tumor indications are engineered for global commercialization. In addition, we are exploring innovative approaches to simplify the manufacturing process through curtailed in vitro culture, non-viral methods, and off-the-shelf CAR products. Some of these techniques, such as short manufacturing processes, have demonstrated potency and safety in the preclinical stage. This strategic approach aims to deliver potent therapies to patients efficiently while managing costs.

Manufacturing

- We continued to maintain the manufacturing success rate of 98% for Carteyva®, close to the level that we obtained in our LBCL registrational clinical trial.

- We have developed our platform process and successfully manufactured lentiviral vectors to produce Carteyva®, further reducing product costs. Analytical and clinical studies have shown comparable results to those of the current lentiviral vectors. Currently, we have completed patient enrollment for the IND study of these vectors.

- We continued to implement our cost reduction plans in 2025, which include procurement of important raw materials from domestic suppliers. As of June 30, 2025, we continued to source materials from domestic suppliers with high quality and lower costs, and in the future, we aim to source additional raw materials from reputable domestic suppliers.

Business Development and Strategic Partnerships

- On April 18, 2025, we entered into the License Agreement with Juno, one of the substantial shareholders of the Company (the "**Substantial Shareholders**") and a connected person of us, pursuant to which we grant Juno a non-exclusive license under the JW sLVV Manufacturing Process and under related know-how (and patents) that are primarily or directly related to, or reasonably necessary or valuable for the development, commercialization, manufacturing or having manufactured the Juno cell therapy products in the field worldwide. This License Agreement is approved by the Independent Shareholders and is effective on June 3, 2025. The aggregate value of the consideration payable by Juno will not be more than USD10 million.

Future and Outlook

Our mission is to deliver transformative therapies through scientific excellence and technological innovation, making high-quality treatments accessible worldwide to benefit patients and their families.

As we look to the future, we reaffirm our commitment to advancing a robust and differentiated pipeline by prioritizing discovery capabilities and sustained R&D investments. Concurrently, we aim to maximize the commercial potential of our approved drug and localized manufacturing. Key growth drivers in the next twelve months include:

- The NMPA's approval of our sNDA relating to Carteyva® as a second line treatment for r/r LBCL, which is expected to occur in 2026.

- The PAS ("**post-approval submission**") of the JW vector in the second half of 2025.

- Data from the ongoing IIT relating to JWCAR201 (dual CAR-T) as a treatment for hematologic malignancies, which is expected to be presented at the Annual Meeting of the American Society for Hematology in December 2025.

BUSINESS REVIEW

Overview

The Company is an independent, innovative biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products. Since our founding in 2016, we have built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases. We are committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry.

Product Pipeline

The following pipeline chart demonstrates the development status of our selected assets as of the date of this report:

Product	Target	Indication	Commercial Rights	Pre-clinical / Phase I / Pivotal / Phase II/III / NDA / Marketed	Partner
JWCAR029/Relmacabtagene Autoleucel (relma-cel)	CD19	3L LBCL	Mainland China, Hong Kong, Macau*	Marketed	JUNO Bristol Myers Squibb Company
		3L FL	Mainland China, Hong Kong, Macau	Marketed	
		3L MCL	Mainland China, Hong Kong, Macau	Marketed	
		2L LBCL	Mainland China, Hong Kong, Macau	NDA	
JWCAR029/Autoimmune	CD19	SLE	Mainland China, Hong Kong, Macau	Phase I	
JWCAR201/Hematology	CD19/20	TBD	Global	IIT and IND enabling	
JWCAR201/Autoimmune	CD19/20	TBD	Global	IIT	
JWCAR239/Hematology Fast CAR	TBD	TBD	Global	Pre-clinical	
JWTCR001	MAGE-A4	various solid tumors	Mainland China, Hong Kong, Macau	Phase I	2seventybio
JWCAR129	BCMA	r/r MM	Mainland China, Hong Kong, Macau	Phase I	JUNO Bristol Myers Squibb Company
JWCAR031	DLL3	SCLC	Mainland China, Hong Kong, Macau	Phase I	JUNO Bristol Myers Squibb Company
JWATM203	AFP	HCC	Greater China and member countries of ASEAN	Phase I	EUREKA
JWATM213	AFP	HCC	Greater China and member countries of ASEAN	Phase I	Lyell EUREKA
JWATM204	GPC3	HCC	Greater China and member countries of ASEAN	Phase I	EUREKA
JWATM214	GPC3	HCC	Greater China and member countries of ASEAN	Phase I	Lyell EUREKA

Abbreviations: LBCL = large B-cell lymphoma; FL = follicular lymphoma; MCL = mantle cell lymphoma; SLE = systemic lupus erythematosus; r/r = relapsed or refractory; MM = multiple myeloma; SCLC = small cell lung cancer; HCC = hepatocellular carcinoma; MAGE-A4 = melanoma associated antigen A4; DLL3 = Delta-like ligand; AFP = alpha-fetoprotein; GPC3 = glypican-3.

* Mainland China, Hong Kong and Macau refer to Mainland China, Hong Kong (China) and Macau (China), respectively.

We are an early entrant into the field of cell-based immunotherapy in China. Cell-based immunotherapies, including CAR-T treatments, are an innovative treatment method that uses human immune cells to fight cancer, representing a paradigm shift in cancer treatment. Our lead product, Carteyva®, is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by us based on a CAR-T cell process platform of Juno (a Bristol Myers Squibb company). Carteyva® has been approved by the NMPA for three indications, including the treatment of adult patients with r/r LBCL after two or more lines of systemic therapy, the treatment of adult patients with r/r follicular lymphoma ("**FL**") in which a relapse occurs within 24 months of second-line or higher systemic treatment, and the treatment of adult patients with r/r mantle cell lymphoma ("**MCL**") after two or more lines of systemic therapy including BTKi. Carteyva® is the first CAR-T product approved as a Category 1 biologics product in China and it is the first CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program and granted priority review and breakthrough therapy designations.

Sales of CAR-T products in China remained relatively stable in 2025, as compared to 2024. Given the unmet medical needs that can be effectively addressed by CAR-T therapies, the market for CAR-T therapies in China is expected to experience strong growth through 2030, according to Frost & Sullivan. We believe that we are well-positioned to take advantage of this growing market, based on the best-in-class potential of our anti-CD19 CAR-T product profile; our robust and differentiated cell therapy pipeline covering hematological cancers, solid tumors, and autoimmune diseases; our fully integrated cell therapy development platform; our leading commercial manufacturing infrastructure and supply chain; and our seasoned management and substantial support from the shareholders of the Company (the "**Shareholders**"). In 2025, we made significant progress on the development of Carteyva® for the treatment of hematological malignancies, progressed development of our products for the treatment of solid tumors, and advanced relma-cel as a potential treatment for SLE, an autoimmune disease widely prevalent in China.

Commercialization

Sales of Carteyva® remained broadly stable versus 2024 despite facing the challenging external environment.

In the first half of 2025, our commercial team enhanced our commercialization strategy, improved efficiency, and expanded our coverage to drive our sales revenue. Currently, we have a robust commercial team with strong commercialization capabilities, including sales, marketing, market access, innovative payment and CAR-T consultants, to commercialize Carteyva® across China.

To build a patient-centric treatment model, we conducted training sessions for each hospital to help physicians and nurses gain a comprehensive understanding of Carteyva® and the entire process from prescription to infusion. Furthermore, we conducted a systematic evaluation of hospitals to ensure the administration of CAR-T products meets our standards.

To improve affordability, we have leveraged the development of China's multi-layer medical insurance system by listing Carteyva® in more local governmental complementary medical insurance programs and health insurance products. As of June 30, 2025, Carteyva® has been listed in more than 90 commercial insurance products and 104 local governmental complementary medical insurance programs. We will continue to expand commercial insurance coverage and explore more innovative payment solutions to improve affordability for patients who are eligible to be treated with Carteyva®.

We have made further progress with the implementation of the manufacturing cost reduction strategies. As of June 30, 2025, we have commenced sourcing key materials from domestic suppliers and going forward we plan to source additional raw materials from domestic suppliers. We continue optimizing our manufacturing operations to improve efficiency and exploring new technologies for process improvement or new process platforms.

We continue to collaborate with stakeholders in the medical industry to establish best practices and industry standards for CAR-T therapies and enhance the administration and monitoring processes of CAR-T therapies to improve patient outcomes. Given the proven efficacy of Carteyva®, the high unmet medical needs of r/r NHL patients and expanded coverage under the multi-layer medical care system in China, together with our strategy and strong commercialization capabilities, we are confident that Carteyva® is well-positioned to benefit more patients in the medium and long term.

Our Product Pipeline

We have developed a robust and differentiated cell-based immunotherapy pipeline with a risk-balanced approach that has shown clear benefits in the field of cell therapies for hematological cancers and provides an opportunity to expand into the nascent field of cell therapies for solid tumors and autoimmune diseases. Our product pipeline features a mix of product candidates targeting both proven and novel tumor antigens. In 2025, we made significant progress on the development of Carteyva® for the treatment of hematological malignancies, expanded our portfolio of products for the treatment of solid tumors, and advanced relma-cel as a potential treatment for SLE, a widely prevalent autoimmune disease. With respect to hematological malignancies, our sNDA relating to Carteyva® as a treatment for adult patients with r/r MCL was accepted by NMPA at the beginning of 2024. Previously the NMPA granted Breakthrough Therapy Designation and Priority Review to Carteyva® for this indication. In August 2024, the NMPA approved our sNDA relating to Carteyva® for the treatment of adult patients with r/r MCL after two or more lines of systemic therapy including BTKi. In addition, we completed patient enrollment in our clinical trial of Carteyva® as a second-line treatment for LBCL in 2024 and submitted an NDA application in the first half of 2025. With respect to solid tumors, we commenced clinical development of cell therapy products directed at MAGE-A4. Moreover, in 2024, we initiated the IND study of relma-cel as a treatment for patients with moderately or severely active SLE, expanding our potential range into the treatment of autoimmune diseases. We believe that the Company may be able to secure a first-mover or early-mover advantage in a highly promising market through the development of these therapies.

We are also developing our other product in the pipeline and progressing into the clinical stage. JWCAR201 is a dual targeting autologous CAR-T cell therapy designed for B-cell malignancies and autoimmune diseases. In the first half of 2024, we announced the commencement of an IIT relating to JWCAR201, and we continued patient enrollment and follow-up through 2025.

The following outlines the current development status of our products and product candidates that are intended for the treatment of hematologic malignancies and autoimmune diseases:

Hematologic Malignancies

Our Core Product Candidate — Carteyva® (relma-cel, R&D code: JWCAR029)

Carteyva®, our lead product, has the potential to be a CAR-T therapy with superior efficacy and safety profile. It targets an antigen called CD19, which is expressed in a broad range of hematological cancers. Lymphomas are hematological cancers involving lymphocytes of the immune system, and LBCL and FL are types of non-Hodgkin's lymphoma ("**NHL**") that affect B-cells within the immune system. In addition to marketing Carteyva® as a third-line treatment for LBCL, r/r FL and r/r MCL, we are also exploring the further clinical potential for Carteyva® by developing relma-cel as a frontline and second-line treatment for LBCL.

Carteyva® is based on a CAR construct that we have in-licensed from Juno for Mainland China, Hong Kong and Macau[2]. Juno's biologics license application for its product based on that same CAR construct ("**Breyanzi**" or "**lisocabtagene**" or "**liso-cel**") was approved by the U.S. FDA for third-line LBCL in February 2021 and for second-line LBCL that is r/r within 12 months of frontline therapy in June 2022.

Third-line LBCL

On September 1, 2021, the NMPA approved our NDA for Carteyva® as a treatment for adult patients with r/r LBCL after two or more lines of systemic therapy. Carteyva® is the first CAR-T product approved as a Category 1 biologics product in China and the sixth approved CAR-T product globally.

Carteyva®'s potential to be a best-in-class CAR-T therapy is based on its superior safety profile and competitive efficacy. Our Phase II registrational clinical trial of Carteyva® as a third-line treatment for LBCL demonstrated efficacy results of best overall response rate ("**ORR**") of 77.6% and best complete response rate ("**CRR**") of 53.5%. In the same trial, severe cytokine release syndrome ("**sCRS**") was observed in 5.1% of treated patients, severe neurotoxicity ("**sNT**") was observed in 3.4% of treated patients, and no treatment-related deaths were reported. In addition, the overall survival ("**OS**") rate was 69.3% after two years and 66.7% after four years, and there were no new safety signals. We reported two years of follow-up results at the Annual Meeting of the American Society of Hematology held in San Diego, California in December 2023. We also reported four years of follow-up results at the Annual Meeting of the American Society of Clinical Oncology for 2024.

Second-line LBCL

In January 2023, we submitted a new IND application for Carteyva® as second-line therapy for transplant-ineligible patients with r/r LBCL. The design is similar to the PILOT study evaluating Breyanzi, based on which the U.S. FDA has approved Breyanzi for second-line treatment of transplant-ineligible patients. The NMPA approved our IND application in March 2023. We enrolled the first patient into this trial in November 2023 and completed patient enrollment in the second half of 2024. The NMPA granted Breakthrough Therapy Designation to Carteyva® for this indication in January 2025, The primary endpoint of the study was met, and we submitted an sNDA in May 2025.

[2] Mainland China, Hong Kong and Macau refer to Mainland China, Hong Kong (China) and Macau (China), respectively.

Third-line FL

With respect to Carteyva® as a third-line treatment for adult patients with r/r FL, the NMPA granted Breakthrough Therapy Designation in September 2020, accepted our sNDA in February 2022, and approved our sNDA in October 2022. Carteyva® has thus become the first CAR-T product approved for the treatment of r/r FL in China.

The NMPA's approval of our sNDA relating to Carteyva® as a third-line treatment for adult patients with r/r FL was based on the 6-months clinical results from cohort B of a single-arm, multi-center pivotal study (the "**RELIANCE**" study) on Carteyva® in adult patients with r/r B cell non-Hodgkin lymphoma in China. The 3-months data was presented at the 63rd Annual Meeting of the American Society of Hematology in December 2021. The cohort B results of the RELIANCE study showed that Carteyva® demonstrated high rates of durable disease response (ORR=100.0%, CRR=85.2% at month 3; ORR=92.6%, CRR=77.8% at month 6) and controllable CAR-T associated toxicities in patients with r/r FL.

In December 2022, we reported cohort B clinical response of this pivotal Phase II RELIANCE study on the efficacy and safety of Carteyva® in adults with r/r FL in China at the 64th Annual Meeting of the American Society of Hematology. As of the data cut-off date of December 17, 2021, based on 28 patients who had been treated with Carteyva® with 11.7 months of median follow-up, Carteyva® demonstrated remarkable clinical responses, achieving high rates of CRR and ORR (best ORR and best CRR were 100.0% and 92.6%, respectively) and a manageable safety profile — only one patient experienced grade 3 or above NT, and no patient experienced grade 3 or above CRS. We are continuing the RELIANCE study, and we currently plan to publish 2 years of follow-up data in 2025.

r/r MCL

We have completed enrollment in a registrational trial in China to evaluate Carteyva® as a treatment for MCL patients who previously received chemotherapy, an anti-CD20 agent, and Bruton tyrosine kinase inhibitors ("**BTKi**"). This is a Phase II, open-label, single-arm, multicenter study which aims to assess the efficacy and safety of Carteyva® in adults with r/r MCL in China. The study enrolled a total of 59 r/r MCL patients who were r/r to second-line or above treatments. Prior therapies must include an anti-CD20 monoclonal antibody, anthracycline-or bendamustine-containing chemotherapy, and BTKi therapy. We plan to follow up on long-term survival for these patients. In August 2024, the NMPA approved our sNDA relating to Carteyva® for the treatment of adult patients with r/r MCL after two or more lines of systemic therapy including BTKi, and Carteyva® is the first cell therapy product approved in China for the treatment of patients with r/r MCL. The NMPA granted Breakthrough Therapy Designation to Carteyva® for this purpose in April 2022, as well as priority review in December 2023.

At the 65th Annual Meeting of the American Society of Hematology in December 2023, we reported preliminary safety and efficacy data for our study of Carteyva® as a treatment for MCL. As of the data cut-off of October 25, 2023, a total of 59 participants had been treated with Carteyva®, demonstrating remarkable clinical responses, with high rates of CRR and ORR (3 months best ORR 81.36%, 3 months best CRR 67.80%). The safety assessment showed that in 59 participants who received Carteyva®, the incidence of severe (grade≥3) CRS was 6.78%, and the incidence of severe (grade≥3) NT was 6.78%.

Our New Product Candidate — JWCAR201

One of our first in-house developed products, JWCAR201, is a dual targeting CD19/20 autologous CAR-T cell therapy designed for B-cell malignancies, which is expected to have a broader range of effectiveness, increased signaling threshold, and significantly reduced risk of relapse due to antigen downregulation or loss that is commonly observed in hematological cancers. In the second half of 2024, we announced the commencement of a first-in-human IIT study relating to JWCAR201, focusing on hematologic malignancies; patient enrollment in this study is currently ongoing; the safety profile is good and preliminary efficacy data is promising. We expect to publish a readout by the end of 2025.

Autoimmune Diseases

Systemic Lupus Erythematosus ("SLE") — Carteyva® (relma-cel, R&D code: JWCAR029)

SLE is a chronic autoimmune disease characterized by the production of autoantibodies and abnormal B-lymphocyte function. The prevalence of SLE in China mainland is approximately 30/100,000 or around 270,000 cases patient-year[3], 40% of SLE patients develop organ damage in the first year, and 50% of patients develop irreversible organ damage within five years of onset. Current standards of care are neither effective nor safe, which addresses the significant unmet medical needs.

B Cell Depletion Therapy ("**BCDT**") has now become one of the primary novel therapy candidates targeted at SLE.

CD19 is widely expressed at all differentiation stages from pre-B cells to plasma cells. Hence, CD19-targeted CAR-T cells may target and deplete B cells or plasma cells that are directly responsible for autoantibody production. Compared with antibodies, CAR-T cell therapy could retain potency over time and rapidly lead to lasting remission. We estimate that at least 15,000 patients are CAR-T eligible in the targeted setting with high treatment willingness.

We received NMPA approval of our IND application relating to relma-cel as a treatment for SLE in April 2023, to evaluate the safety, tolerability, and pharmacokinetic profile of relma-cel in Chinese patients with moderately or severely active SLE, and we completed patient enrollment by the end of 2024. We have already demonstrated successful manufacture of CAR-T cells for SLE patients in both IIT/IND studies and observed a well-managed safety profile, significant improvement of clinical symptoms as well as complete depletion of B-cells.

We believe that the Company may be able to secure a first-mover or early-mover advantage in the highly promising market for treatment of SLE in China through the development of such therapy.

[3] Rees F, Doherty M, Grainge MJ, et al. The Worldwide Incidence and Prevalence of Systemic Lupus Erythematosus: A Systematic Review of Epidemiological Studies. Rheumatology. 2017; 56(11): 1945– 1961. Applied 30 cases/100,000 and assuming 900 million as China adult population in 2017.

Our New Product Candidate — JWCAR201

One of our first in-house developed products, JWCAR201, is a dual targeting CD19/20 autologous CAR-T cell therapy designed for autoimmune diseases, which is expected to have a broader range of effectiveness and increased signaling threshold. In late 2024, we announced the commencement of a first-in-human IIT study relating to JWCAR201, focusing on autoimmune diseases, and patient enrollment in this study is currently ongoing.

Solid Tumors

The following outlines the current development status of our product candidates that are intended for the treatment of solid tumors:

JWTCR001

JWTCR001 is a specific cell therapy product directed to MAGE-A4 (including any mutations, fragments, modifications or derivatives of the engineered TCR binding MAGE-A4). MAGE-A4 is a highly prevalent antigen in a wide variety of malignant tumors, including non-small cell lung cancer, melanoma, bladder, head and neck, gastroesophageal, and ovarian cancers, and thus an ideal target indication for TCR-T therapy. We have utilized the CTBR12 TGF-beta ("**FLIP**") receptor technique developed by Regeneron, which potentially increases efficacy. Early phase clinical trials have previously demonstrated that TCR-T cell therapies targeting MAGE-A4 can have meaningful clinical efficacy for the treatment of MAGE-A4-expressing solid tumors. The biological license application ("**BLA**") for treatment of synovia sarcoma was accepted by the U.S. FDA on January 31, 2024, and priority review has been granted.

In October 2022, we established a strategic alliance with 2seventy bio to develop and commercialize a cell therapy product directed to MAGE-A4 (including any mutations, fragments, modifications or derivatives of the engineered binding element for MAGE-A4) in oncology indications. 2seventy Bio's oncology and autoimmune research and development programs were acquired by Regeneron in 2024, and such acquisition has not had any impact on the progress of our collaboration. The agreement is focused on the technologies and know-how possessed by Regeneron and includes prospects for the development and commercialization of the product in Greater China based on addressable patient populations and unmet medical needs. With Regeneron's support, we believe that the Company may be able to secure a first-mover or early-mover advantage in a highly promising market through the development of such a therapy. We have established our manufacturing process for a product directed to MAGE-A4, and patient enrollment in this IIT was initiated in the first quarter of 2024.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"): We cannot guarantee that we will be able to successfully develop or ultimately market Carteyva® in indications beyond the current NMPA-approved label, or to successfully develop or ultimately market our other pipeline products. Shareholders and potential investors of the Company are advised to exercise due care when dealing with the shares of the Company.

Discovery and Pre-clinical Research

Our early research and development efforts are focused on engineering innovative pipeline products that leverage our infrastructure and expertise to their fullest potential. Following the successful registration and commercialization of our personalized anti-CD19 CAR product in China, we have established an efficient framework for collecting, manufacturing, and delivering autologous CAR therapies to patients in need. Building on this success, our early research aims to further leverage this framework by developing new autologous products with enhanced features and expanding their commercialization to international markets without regional restrictions. With global commercialization envisioned, we intend to engineer our new pipeline products in a way that will maximize their value to us.

Our new pipeline products will primarily focus on addressing unmet needs for hematological cancers, solid tumors, and autoimmune diseases, with the aim of overcoming key challenges and limitations in this field. Alongside developing new products through early research, we also invest substantial effort into strengthening our existing pipeline through process modifications and the incorporation of additional components. These products will incorporate additional "Armor" elements that are designed in-house to enhance the anti-cancer function of CAR therapies. By combining these Armor elements with the CAR products, we aim to prolong the duration of treatment in patients and make it less responsive to suppressive signals produced by tumors, thereby achieving better outcomes for patients.

Furthermore, all these new products will benefit from our next-generation product processing method, which has been internally developed to accelerate manufacturing, reduce costs, and maintain the product in an optimal state compared to conventional methods.

One of our first in-house developed products is JWCAR201, a dual targeting CD19/20 autologous CAR-T cell therapy designed for B-cell malignancies and autoimmune diseases. By incorporating dual targeting, this product is expected to have a broader range of effectiveness, increase the signaling threshold, and significantly reduce the risk of relapse due to antigen downregulation or loss, a common phenomenon observed in hematological cancers. Additionally, we plan to equip this product with enhanced Armored elements to improve performance and shield it from suppressive factors produced by the tumor's defense systems. Our next generation processing techniques will be deployed to manufacture this product, aiming to deliver a more potent, rapid, and cost-effective therapy. The CAR product for autoimmune diseases was delivered to the clinical stage in the third quarter of 2024, while the enhanced CAR product for B-cell malignancies is currently expected to be delivered to the clinical stage by the third quarter of 2025. Both products are intended for commercialization both within and outside China.

In addition, we are developing two new CAR products for solid tumor indications. Both products incorporate enhanced Armored elements and leverage our next-generation cellular processes, designed to increase product potency while reducing manufacturing costs and time.

Lastly, we are exploring innovative approaches to simplify the manufacturing process. We are investigating the feasibility of short process and non-viral methods that involve genomic editing and off-the-shelf CAR products for various indications. These approaches may potentially expedite the delivery of therapies to patients and reduce overall production costs.

Manufacturing

In June 2020, we received a production license from Jiangsu Province authorities for our new commercial manufacturing facility in Suzhou. This facility provides approximately 10,000 square meters for commercial and clinical manufacturing in compliance with Good Manufacturing Practice ("**GMP**") and Quality Management System ("**QMS**") standards.

With current regulatory approval, we can meet manufacturing needs for both commercial and clinical supplies and have maintained a high manufacturing success rate of 98% since our LBCL registration clinical trial. After the initial product launch, we gained multiple approvals for manufacturing capacity expansion in the fourth quarter of 2022 and the first quarter of 2023.

As a critical material, a sustainable lentiviral vector supply is necessary to ensure the manufacturing and supply of our final product. We have developed a platform process and successfully manufactured vectors to support more clinical programs. Furthermore, our vector manufacturing platform has successfully produced lentiviral vectors for the manufacture of Carteyva®. Analytical and clinical studies have shown comparable results to those of the current lentiviral vectors. Currently, we have completed patient enrollment for the IND study of these vectors.

Business Development and Strategic Partnerships

Our business development team plays a pivotal role in driving strategic growth for our business. They will pursue partnerships to bolster our late-stage and early-stage pipeline of potential molecules, and access technologies that complement our research and development efforts. In addition, they are supporting the development of our existing strategic partnerships, including BMS etc.

- On April 18, 2025, we entered into the License Agreement with Juno, one of the Substantial Shareholders and a connected person of us, pursuant to which we grant Juno a non-exclusive license under the JW sLVV Manufacturing Process and under related know-how (and patents) that are primarily or directly related to, or reasonably necessary or valuable for the development, commercialization, manufacturing or having manufactured the Juno cell therapy products in the field worldwide. The non-exclusive out-licensing of the License Agreement not only highlights our research and development capabilities but also affirms its leadership in cell therapy technologies. Beyond the immediate financial benefit of the upfront payment and the further financial benefit of the Additional Payment, the License Agreement provides us with an additional and reliable supply of Vector, which constitutes an essential component for the manufacturing of our core product, Carteyva®, while simultaneously enabling us to conserve cash for use in its operations. The entering into of the License Agreement strengthens our position in the market, enhances our production capabilities, and supports our long-term growth and success in the cell therapy field. This License Agreement is approved by the Independent Shareholders and is effective on June 3, 2025. The aggregate value of the consideration payable by Juno will not be more than USD10 million.

Beyond these initiatives, we remain actively engaged with potential partners to explore a range of opportunities aimed at accelerating value creation. These include in-licensing, out-licensing, and strategic partnerships.

Future and Development

Our vision is becoming an innovation leader in cell immunotherapy; we intend to focus on pursuing the following strategies to achieve that vision:

- Continue to drive full-scale commercialization of Carteyva®.
- Solidify our leadership in hematology by continuing to develop Carteyva® for earlier lines of treatment and additional indications, as well as further expanding clinical development for autoimmune diseases.
- Leverage our integrated cell therapy platform to expand into the solid tumor market.
- Continuously enhance our manufacturing capability and implement a cost reduction plan through innovation and scale.
- Grow our business through in-licensing opportunities, partnerships, and selective acquisitions, as well as in-house R&D.

FINANCIAL REVIEW

Six Months Ended June 30, 2025 Compared to Six Months Ended June 30, 2024

IFRS Measure:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**106,346**	86,815
Cost of sales	**(41,229)**	(43,070)
Gross profit	**65,117**	43,745
Other income	**4,282**	1,884
Other gains and losses	**(160,116)**	(6,729)
Selling expenses	**(58,494)**	(76,172)
General and administrative expenses	**(32,190)**	(59,233)
Research and development expenses	**(92,041)**	(151,008)
Finance income	**12,423**	13,299
Finance costs	**(6,246)**	(6,053)
Finance costs — net	**6,177**	7,246
Loss before tax	**(267,265)**	(240,267)
Income tax expense	**—**	—
Loss for the period	**(267,265)**	(240,267)
Other comprehensive (expense) income		
Items that will not be reclassified to profit or loss:		
Exchange differences arising on translation from functional currency to presentation currency	**(1,158)**	15,829
Items that may be reclassified subsequently to profit or loss:		
Exchange differences arising on translation of foreign operations	**3,228**	3,719
Other comprehensive income for the period	**2,070**	19,548
Total comprehensive expense for the period	**(265,195)**	(220,719)
LOSS PER SHARE		
— Basic and diluted *(RMB)*	**(0.64)**	(0.58)

1. Revenue

Revenue was RMB106.3 million for the six months ended June 30, 2025, an increase of 22.5% compared to RMB86.8 million for the six months ended June 30, 2024. Revenue was generated from (i) sales of Carteyva®, our product currently under commercialization, which was recognized at the point of infusion; and (ii) a non-exclusive license granted to Juno under the JW sLVV Manufacturing Process and related know-how (including patents), which was recognized at point in time.

Carteyva® has been approved for treating adult patients with r/r LBCL, r/r FL and r/r MCL. For the six months ended June 30, 2025, sales of Carteyva® was RMB81.2 million, remained broadly stable versus that for the six months ended June 30, 2024 despite facing the challenging external environment and the control on selling expenses. With a robust commercial team, enhanced commercialization strategy and expanded market coverage, we anticipate an increase in revenue from the sales of Carteyva® for the second half of 2025.

On April 18, 2025, we entered into the License Agreement with Juno and granted it a non-exclusive license under the JW sLVV Manufacturing Process and under related know-how (and patents) that are primarily or directly related to, or reasonably necessary or valuable for the development, commercialization, manufacturing or having manufactured the Juno Cell Therapy Products in the field worldwide. The aggregate value of the consideration payable by Juno will not be more than USD10 million. For the six months ended 2025, we recognized revenue in the amount of RMB25.1 million at point in time.

The following table sets forth a breakdown of revenue from our products and grant of a license for the period indicated:

	Six months ended June 30,			
	2025		2024	
	RMB'000 **(Unaudited)**	**%**	*RMB'000* (Unaudited)	*%*
Carteyva®	**81,239**	**76.4**	86,815	100.0
Grant of a non-exclusive license	**25,107**	**23.6**	—	—
Total revenue	**106,346**	**100.0**	86,815	100.0

2. Cost of Sales

Cost of sales was RMB41.2 million for the six months ended June 30, 2025, as compared to RMB43.1 million for the six months ended June 30, 2024. Cost of sales primarily consists of raw material costs, staff costs, depreciation and amortization, manufacturing overhead and others.

The following table sets forth a breakdown of cost of sales for the period indicated:

	Six months ended June 30,			
	2025		2024	
	RMB'000	**%**	*RMB'000*	*%*
	(Unaudited)		(Unaudited)	
Carteyva®	**39,699**	**96.3**	43,070	100.0
Grant of a non-exclusive license	**1,530**	**3.7**	—	—
Total cost of sales	**41,229**	**100.0**	43,070	100.0

3. Gross Profit and Gross Profit Margin

Gross profit represents revenue minus cost of sales. Gross profit margin represents gross profit as a percentage of revenue.

Gross profit from sales of products was RMB41.5 million and gross profit margin of sales of products was 51.1% for the six months ended June 30, 2025, which remains stable as compared to RMB43.7 million and 50.4%, respectively, for the six months ended June 30, 2024.

Gross profit and gross profit margin of grant of a license were RMB23.6 million and 93.9% for the six months ended June 30, 2025, respectively.

4. Selling Expenses

Selling expenses mainly consist of (i) staff costs for selling and marketing personnel; (ii) related expenses of marketing and promotion activities; and (iii) professional service fee and office expenses.

Selling expenses were RMB58.5 million, accounting for 72.0% of product revenue for the six months ended June 30, 2025, compared with RMB76.2 million, or 87.7% of product revenue for the six months ended June 30, 2024. The improvement was primarily attributable to the execution of the Group's optimization strategies in relation to its commercial initiatives, coupled with the implementation of its organization effectiveness program since the second half of 2024, which led to a decrease of selling expense by 23.2% compared to the prior-year period.

5. General and Administrative Expenses

The administrative expenses of the Group mainly consist of (i) labor cost for the administrative personnel; (ii) professional service fees incurred by the Group; (iii) depreciation and amortization; and (iv) other administrative and office expenses.

General and administrative expenses decreased from RMB59.2 million for the six months ended June 30, 2024 to RMB32.2 million for the six months ended June 30, 2025. The decrease was primarily attributable to the streamlined organization and control on costs, which resulted in a decrease in labor cost for the administrative personnel by 48.1% and professional service fees by 55.8% respectively.

6. R&D Expenses

The R&D expenses of the Group mainly consist of (i) labor cost for the R&D staff; (ii) testing and clinical fees; (iii) depreciation and amortization of the equipment and facilities used by the R&D department; (iv) cost of materials used in R&D activities; and (v) office and other expenses used by the R&D department.

R&D expenses decreased from RMB151.0 million for the six months ended June 30, 2024 to RMB92.0 million for the six months ended June 30, 2025. The decrease was primarily attributable to an enhanced operation efficiency and optimized R&D strategy including: (i) optimization of the Group's R&D workforce; (ii) a decrease in R&D materials; and (iii) a decrease in testing and clinical fees.

7. Other Income

Other income amounted to RMB4.3 million for the six months ended June 30, 2025, as compared to RMB1.9 million for the six months ended June 30, 2024. Other income in both periods was related to government grants.

8. Other Gains and Losses

The following table provides a breakdown of other gains and losses for the six months ended June 30, 2025 and 2024:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Impairment of license	**152,602**	—
Net foreign exchange losses	**6,800**	6,998
Others	**714**	(269)
Other gains and losses	**160,116**	6,729

Other gains and losses increased from RMB6.7 million for the six months ended June 30, 2024 to RMB160.1 million for the six months ended June 30, 2025. This increase was primarily attributable to the recognition of impairment of license that was related to product JWATM204/214 based on an adjustment noted in the valuation report prepared by an independent valuer, which took into account a variety of factors including the level of complexity of R&D pathways, the time and resources that might be required in advancing in-depth analysis with clinical data, and the overall R&D investment efforts required to work toward commercialization. The Company estimated that these factors may affect the revenue growth rate, which gave rise to a decline in the recoverable amount of the cash-generating unit and caused the recognition of impairment loss of RMB152.6 million.

9. Income Tax Expense

For the six months ended June 30, 2025 and 2024, we did not incur any income tax expense, as we did not generate taxable income in either period.

10. Loss for the Period

As a result of the above items, loss for the period was RMB267.3 million for the six months ended June 30, 2025, as compared to RMB240.3 million for the six months ended June 30, 2024. The increase was mainly due to a RMB152.6 million provision for impairment of the license related to product JWATM204/214, reflecting an adjustment in the independent valuation report. The effect of the impairment loss was largely offset by a reduction of RMB126.5 million in recurring operation loss compared to the prior-year period, which was primarily attributable to: (i) increased revenue and gross profit generated from sales of Carteyva® and grant of a license; (ii) decreased general and administrative expenses due to streamlined organization and control on professional service fees; (iii) decreased selling expenses resulting from Group's optimization strategies in relation to its commercial initiatives and commercial workforce; and (iv) decreased R&D expenses attributable to workforce optimization and a decrease in expenses relating to R&D materials, testing and clinical fees.

11. Non-IFRS Measure

To supplement the Group's condensed consolidated financial statements, which are presented in accordance with IFRS, we also use adjusted loss for the period as an additional financial measure, which is not required by, or presented in accordance with IFRS. We believe that these adjusted measures provide useful information to Shareholders and potential investors in understanding and evaluating our consolidated results of operations in the same manner as they help our management.

Adjusted loss was RMB103.3 million for the six months ended June 30, 2025, representing a decrease of RMB111.4 million from RMB214.7 million for the six months ended June 30, 2024. The decrease was primarily attributable to (i) increased revenue and gross profit generated from sales of Carteyva® and grant of a license; (ii) decreased general and administrative expenses due to streamlined organization and control on professional service fees; (iii) decreased selling expenses resulting from Group's optimization strategies in relation to its commercial initiatives and commercial workforce; and (iv) decreased R&D expenses attributable to workforce optimization and a decrease in expenses relating to R&D materials, testing and clinical fees.

Adjusted loss for the period represents the loss for the period excluding the effect of certain non-cash items and one-time events, namely share-based compensation expenses, impairment of license and net foreign exchange losses. The term adjusted loss for the period is not defined under IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, our results of operations or financial condition as reported under IFRS. Our presentation of this adjusted figure may not be comparable to similarly titled measures presented by other companies. However, we believe that this non-IFRS measure reflects our core operating results by eliminating potential impacts of items that our management do not consider to be indicative of our core operating performance, and thus, facilitates comparisons of core operating performance from period to period and company to company to the extent applicable. The table below sets forth a reconciliation of loss to adjusted loss for the periods indicated:

	Six months ended June 30,	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss for the period	**(267,265)**	(240,267)
Added:		
Share-based compensation expenses	**4,536**	18,557
Impairment of license	**152,602**	—
Net foreign exchange losses	**6,800**	6,998
Adjusted loss for the period (Non-IFRS)	**(103,327)**	(214,712)

Selected Data from Statement of Financial Position

	As at June 30, 2025	As at December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Total current assets	**747,045**	808,673
Total non-current assets	**672,396**	871,691
Total assets	**1,419,441**	1,680,364
Total current liabilities	**470,349**	465,054
Total non-current liabilities	**40,484**	46,145
Total liabilities	**510,833**	511,199
Net current assets	**276,696**	343,619

12. Liquidity and Sources of Funding and Borrowing

As at June 30, 2025, current assets amounted to RMB747.0 million, including cash and cash equivalents of RMB646.9 million and other current assets of RMB100.1 million. As at the same date, current liabilities amounted to RMB470.3 million, primarily including borrowings of RMB320.5 million, trade and other payables of RMB105.3 million, and contract liabilities of RMB29.4 million.

In the first half of 2025, we strictly controlled our cash expenditures and actively diversified and expanded our financing channels to provide financial assurance for our future development. As of June 30, 2025, we have unsecured bank borrowings in the amount of RMB339.8 million.

As of June 30, 2025, bank balances and cash were RMB646.9 million, representing a net cash outflow of RMB110.5 million for the six months ended June 30, 2025 compared to RMB136.9 million for the six months ended June 30, 2024. The cash outflow was primarily due to payments of selling expenses, general and administrative expenses, R&D expenses, and payment of costs of manufacturing and repayments of bank loans. These payments were partially offset by proceeds from bank loans.

During the six months ended June 30, 2025, the Group was unable to comply with the covenants in respect of a bank loan with a carrying amount of RMB74.5 million as at June 30, 2025. The Directors immediately commenced renegotiation of the terms of the loan with the relevant bank and as at June 30, 2025, the negotiation has not been completed and the lender is still considering whether to waive its right to demand immediate payment, therefore the loan has been classified as current liabilities.

As at the date of this report, the negotiation is still in progress and the Directors are confident that their negotiation with the lender will ultimately reach a successful conclusion. In any event, should the lender call for immediate repayment of the loan, the Directors believe that adequate alternative sources of finance are readily available to ensure that there will be no material adverse effect to the continuing operations of the Group.

13. Key Financial Ratios

The following table sets forth the key financial ratios of the Group as of the dates indicated:

	As at June 30, 2025	As at December 31, 2024
Current ratio[1]	**1.6**	1.7
Ratio of total liabilities to total assets[2]	**0.4**	0.3
Gearing ratio[3]	**N/A[4]**	N/A[4]

(1) Current ratio equals current assets divided by current liabilities as of the date indicated.

(2) Ratio of total liabilities to total assets equals total liabilities divided by total assets as of the date indicated.

(3) Gearing ratio is calculated using interest-bearing borrowings less bank balances and cash divided by total equity and multiplied by 100%.

(4) Gearing ratio is not applicable as our interest-bearing borrowings less bank balances and cash was negative.

14. Material Investments

We did not make any material investments during the six months ended June 30, 2025.

15. Material Acquisitions and Disposals

We did not engage in any material acquisitions or disposals during the six months ended June 30, 2025.

16. Pledge of Assets

As of June 30, 2025, the Group had no pledge of assets.

17. Contingent Liabilities

As of June 30, 2025, we did not have any material contingent liabilities.

18. Foreign Exchange Exposure

The Group mainly operated in Mainland China and a majority of its transactions were settled in RMB. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the Reporting Period. Differences arising on settlement or translation of monetary items are recognized in profit or loss. Expect for certain bank balances and cash, other receivables and prepayments, and trade and other payables denominated in foreign currencies, the Group did not have significant foreign currency exposure from its operations as at June 30, 2025. The management seeks to limit our exposure to foreign currency risk by closely monitoring and minimizing its net foreign currency position. During the Reporting Period, the Group did not enter into any currency hedging transactions.

19. Employees and Remuneration

As of June 30, 2025, we had 292 employees representing a decrease of 9.6% from 323 employees as of June 30, 2024. The total remuneration cost (including Directors' emoluments) incurred by the Group for the six months ended June 30, 2025 was RMB74.5 million, as compared to RMB128.0 million for the six months ended June 30, 2024.

The remuneration of the employees of the Group comprises salaries, bonuses, employees provident fund and social security contributions, other welfare payments and share-based compensation expenses. In accordance with applicable Chinese laws, the Group has made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for the Group's employees.

To maintain the quality, knowledge and skill levels of the Group's workforce, the Group provides its employees with trainings regularly, including induction training for new employees and other trainings on health and safety, professional development, technical skills development and management.

The Company has also adopted the Pre-IPO Incentivization Scheme, the Restricted Share Unit Scheme, the Post-IPO Incentivization Scheme and the Post-IPO Restricted Share Unit Scheme. Please refer to the section headed "Share Incentivization Schemes" in this interim report for further details.

EVENTS AFTER THE REPORTING PERIOD

There have been no significant events since the end of the Reporting Period.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the CG Code as its own code of corporate governance during the six months ended June 30, 2025.

Except as expressly described below, the Company has complied with all applicable code provisions set out in Part 2 of the CG Code during the six months ended June 30, 2025.

Separation of the Roles of the Chairman of the Board and Chief Executive Officer

Pursuant to code provision C.2.1 in Part 2 of the CG Code, the roles of the Chairman and CEO should be separate and should not be performed by the same individual. Following the appointment of Mr. Liu as the CEO and an executive Director, Dr. Li remained as the interim Chairman to provide support and facilitate a smooth transition, resigned as the CEO and has been redesignated as a non-executive Director. Upon the aforesaid changes taking effect from July 31, 2024, the roles of Chairman and CEO had been separately performed by Dr. Li and Mr. Liu, respectively. It follows that the Company had been in full compliance with code provision C.2.1 in Part 2 of the CG Code with effect from July 31, 2024 to March 13, 2025, on which Mr. Liu was appointed the Chairman following the stepping down of Dr. Li from his role as the Chairman. Upon Mr. Liu's appointment as the Chairman, Mr. Liu assumes the dual roles of the Chairman and the CEO. Notwithstanding what is provided under the code provision C.2.1 in Part 2 of the CG Code, the Board has confidence in vesting the roles of both the Chairman and the CEO in Mr. Liu and believes that this will ensure the Group has consistent leadership and could make and implement the business strategies of the Group more effectively. Therefore, the Board considers that the deviation from the code provision C.2.1 in Part 2 of the CG Code is appropriate in such circumstance. In addition, under the supervision of the Board which currently comprised of an executive Director, four non-executive Directors and three independent non-executive Directors, the Board is appropriately structured with balance of power to provide sufficient checks to protect the interests of the Company and its shareholders.

The Board will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted its own code of conduct regarding securities transactions, namely the Code for Securities Transactions by Directors (the "**Securities Transactions Code**"), which applies to all Directors on terms no less than the required standard indicated by the Model Code.

Having made specific enquiries of all Directors, each of the Directors has confirmed that he or she has complied with the required standards as set out in the Securities Transactions Code during the six months ended June 30, 2025.

INTERIM DIVIDEND

The Board has resolved not to recommend the payment of interim dividend for the six months ended June 30, 2025 (six months ended June 30, 2024: Nil).

AUDIT COMMITTEE

The Board has established the Audit Committee which is currently chaired by an independent non-executive Director, Mr. Kin Cheong Kelvin Ho, and consists of another independent non-executive Director, Mr. Peng Kuan Chan, and one non-executive Director, Ms. Xing Gao. The primary duties of the Audit Committee are to assist the Board by monitoring the Company's ongoing compliance with the applicable laws and regulations that governs its business operations, providing an independent view on the effectiveness of the Company's internal control policies, financial management processes and risk management systems.

The Audit Committee had, together with the management and external auditor of the Company, reviewed the accounting principles and policies adopted by the Group and the unaudited condensed consolidated financial statements for the six months ended June 30, 2025.

PRINCIPAL RISKS AND UNCERTAINTIES

The following list is a summary of certain principal risks and uncertainties involved in our operations, some of which are beyond our control:

Risks Relating to Our Financial Position

- We have incurred significant losses since our inception, and we expect to continue to incur losses for the foreseeable future;

- An impairment in the carrying value of intangible assets could have a material adverse effect on our financial condition and results of operations.

Risks Relating to Our Business

- Changes in international trade or investment policies and barriers to trade or investment, the ongoing conflict and trade tension war between the U.S. and China may have an adverse effect on our business and expansion plans;

- We operate in a rapidly changing industry and we face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do, or developing product candidates or treatments that are safer, more effective, more effectively marketed or cost less than ours, or receive regulatory approval or reach the market earlier. As a result, our product candidates may not achieve the sales we anticipate and could be rendered non-competitive or obsolete;

- Our proprietary CAR-T preparation technologies and the manufacturing platform for our CAR-T product candidates represent emerging approaches to cancer treatment that face significant challenges and hurdles;

- Clinical development of biopharmaceutical products involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results;

- If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates;

- We may not be successful in our efforts to build or in-license a pipeline of new product candidates. If we fail to do so, our commercial opportunity will be limited;

- We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success.

Risks Relating to Extensive Government Regulation

- All material aspects of the research, development, manufacturing and commercialization of biopharmaceutical products are heavily regulated. Any failure to comply with existing regulations and industry standards, or any adverse actions by the NMPA or other comparable regulatory authorities against us, could negatively impact our reputation and our business, financial condition, results of operations and prospects;

- The regulatory approval processes of the NMPA and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain, or experience delays in obtaining, regulatory approval for our product candidates, our business will be substantially harmed;

- Changes in government regulations or in practices relating to the pharmaceutical and biopharmaceutical industries, including healthcare reform in China, and compliance with new regulations may result in additional costs;

- Even if we are able to commercialize any approved product candidates, the products may become subject to unfavorable pricing regulations, or to unfavorable changes in national or third-party reimbursement practices, which could harm our business.

Risks Relating to Manufacturing of Our Product Candidates

- Our product candidates are cell therapies. The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to development or scaling-out of our manufacturing capabilities. If we encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure;

- Cell-based therapies rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.

Risks Relating to Commercialization of Our Product Candidates

- The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small, and our projections regarding the size of the addressable market may be incorrect;

- We may not be successful in achieving cost of goods at commercial scale that provide for an attractive margin. We believe that our current, robust manufacturing processes are fit for commercial scale and we anticipate they will enable commercial supply at an economical cost. However, we have not yet established manufacturing capacity at sufficient commercial scale and may underestimate the cost and time required to do so, or overestimate cost reductions from economies of scale that can be realized with our manufacturing processes. We may ultimately be unable to manage the cost of goods for our product candidates to levels that will allow for a margin in line with our expectations and return on investment if and when those product candidates are commercialized;

- Product liability claims or lawsuits could cause us to incur substantial liabilities, and our insurance coverage may be inadequate to protect us from all the liabilities we may incur;

- The increasing use of social media platforms presents new risks and challenges.

Risks Relating to Our Intellectual Property Rights

- We depend on intellectual property licensed from third parties, and termination of any of these licenses or disruption to our business relationship with our licensors could result in monetary damages or the loss of significant rights, which would harm our business;

- If we or our licensors are unable to obtain and maintain adequate patent and other intellectual property protection for our product candidates and other intellectual property, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully develop and commercialize any of our product candidates or technologies may be adversely affected;

- If we determine that our intellectual property rights (including rights in-licensed from third parties) or other intangible assets are impaired, our results of operations and financial condition may be adversely affected;

- Even if we are able to obtain patent protection for our product candidates, the life of such protection, if any, is limited, and third parties could be able to circumvent our patents by developing similar or alternative products and technologies in a non-infringing manner, or develop and commercialize products and technologies similar or identical to ours and compete directly against us after the expiration of our patent rights, if any, and our ability to successfully commercialize any product or technology would be materially adversely affected.

Risks Relating to Our Doing Business in China

- The biopharmaceutical industry in China is highly regulated and such regulations are subject to change, which may affect approval and commercialization of our product candidates;
- Changes in the political and economic policies of the PRC government may materially and adversely affect our business, financial condition and results of operations and may result in our inability to sustain our growth and expansion strategies;
- Our business benefits from certain financial incentives and preferential policies granted by local governments. Expiration of, or changes to, these incentives or policies would have an adverse effect on our results of operations.

However, the above is not an exhaustive list. Investors are advised to make their own judgment or consult their own investment advisors before making any investment in the Shares.

For further details, please refer to the section headed "Risk Factors" in the Prospectus.

CHANGES IN DIRECTORS' INFORMATION

Name of Director	Change
Mr. Min Liu	Mr. Liu has been appointed as Chairman with effect from March 13, 2025.
Dr. Li	Dr. Li has stepped down as Chairman with effect from March 13, 2025.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries have purchased, redeemed or sold any of the Company's listed securities (including sale of treasury shares) during the six months ended June 30, 2025. As of June 30, 2025, the Company did not hold any treasury shares of the Company.

USE OF NET PROCEEDS FROM LISTING

Our shares were listed on the main board of the Stock Exchange on November 3, 2020. The Group received net proceeds (after deducting the underwriting fees and related costs and expenses) from the issue of new shares by the Company in its Listing and the subsequent over-allotment option partially exercised by the Joint Global Coordinators approximately HKD2,495.8 million.

The net proceeds (adjusted on a pro rata basis based on the actual net proceeds) (the "**Net Proceeds**") have been and will be utilized in accordance with the purposes set out in the announcement dated August 27, 2025, which the Board has resolved to change and revise the allocation of the Net Proceeds and the Unutilized Net Proceeds (as shown below). As of June 30, 2025, unutilized net proceeds from the issue of new shares by the Company in its Listing (including the partial exercise of the over-allotment option by the Joint Global Coordinators) (the "**Unutilized Net Proceeds**") amounted to HKD309.69 million.

The table below sets out the planned applications of the net proceeds and actual usage up to June 30, 2025:

Intended Applications	Amount of Net Proceeds *(HKD million)*	Percentage of total Net Proceeds	Net Proceeds brought forward for the Reporting Period *(HKD million)*	Actual usage for the Reporting Period *(HKD million)*	Unutilized Net Proceeds as at June 30, 2025 *(HKD million)*
Research and development activities relating to treatment of hematologic malignancies (including treatment of first-line and second-line LBCL, r/r FL, MCL, ALL, and other programs initiated by the Company using relma-cel)	200.00	24.53%	13.00	11.34	1.66
Research and development activities relating to treatment of solid tumors (including treatment of various solid tumors targeting MAGE-A4 (including JWTCR001), treatment of SCLC and other programs initiated by the Company targeting DLL3 (including JWCAR031), and treatment of HCC and other programs initiated by the Company targeting GPC3 (including JWATM204/JWATM214))	100.00	12.77%	57.31	24.31	33.00
Research and development activities relating to treatment of autoimmune diseases (including treatment of SLE and other programs initiated by the Company using relma-cel)	240.00	29.44%	136.20	11.20	125.00
Potential collaborations, acquisitions and in-licensing opportunities (including potential future collaboration with Acepodia)	100.00	12.27%	100.00	—	100.00
Developing and upgrading technologies, manufacturing platform capabilities and developing new therapy areas	95.00	11.65%	95.00	44.97	50.03
Working capital and general corporate purposes	80.19	9.84%	2.25	2.25	—
Total	815.19	100.0%	403.76	94.07	309.69

Change in Use of Net Proceeds from Listing

The Board, having considered the reasons set out below under the heading "Reasons for the Change in Use of Net Proceeds," has resolved to change the use of the Unutilized Net Proceeds. The change and the revised allocation of the Net Proceeds and the Unutilized Net Proceeds are set out below:

Original use of Net Proceeds as of June 30,2025	Original Allocation of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Percentage of total Net Proceeds	Amount of utilized Net Proceeds as of June 30, 2025 *(HKD million)*	Amount of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Changed use of proceeds as of June 30,2025	Revised allocation of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Revised percentage of Unutilized Net Proceeds
1. Research and development activities relating to treatment of hematologic malignancies (including treatment of first-line and second-line LBCL, r/r FL, MCL, ALL, and other programs initiated by the Company using relma-cel)	200.00	24.53%	198.34	1.66	1. Research and development activities relating to treatment of hematologic malignancies (including treatment of second-line LBCL, r/r FL, MCL, and other programs initiated by the Company using relma-cel)	30.00	9.69%
2. Research and development activities relating to treatment of solid tumors (including treatment of various solid tumors targeting MAGE-A4 (including JWTCR001), treatment of SCLC and other programs initiated by the Company targeting DLL3 (including JWCAR031),and treatment of HCC and other programs initiated by the Company targeting GPC3 (including JWATM204/ JWATM214))	100.00	12.27%	67.00	33.00	2. Research and development activities relating to treatment of solid tumors (including treatment of various solid tumors targeting MAGE-A4 and other potential programs initiated by the Company)	20.00	6.46%
3. Research and development activities relating to treatment of autoimmune diseases (including treatment of SLE and other programs initiated by the Company using relma-cel)	240.00	29.44%	115.00	125.00	3. Research and development activities relating to treatment of autoimmune diseases (including treatment of SLE and other programs initiated by the Company using relma-cel)	50.00	16.15%

Original use of Net Proceeds as of June 30,2025	Original Allocation of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Percentage of total Net Proceeds	Amount of utilized Net Proceeds as of June 30, 2025 *(HKD million)*	Amount of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Changed use of proceeds as of June 30,2025	Revised allocation of Unutilized Net Proceeds as of June 30, 2025 *(HKD million)*	Revised percentage of Unutilized Net Proceeds
4. Potential collaborations, acquisitions and in-licensing opportunities (including potential future collaboration with Acepodia)	100.00	12.27%	—	100.00	4. Potential collaborations, acquisitions and in-licensing opportunities	60.00	19.37%
5. Developing and upgrading technologies, manufacturing platform capabilities and developing new therapy areas	95.00	11.65%	44.97	50.03	5. Developing and upgrading technologies, manufacturing platform capabilities and developing new therapy areas (including studies relating to dual CAR-T targeting CD19/20 and other potential research and development activities.)	120.00	38.75%
6. Working capital and general corporate purposes	80.19	9.84%	80.19	—	6. Working capital and general corporate purposes	29.69	9.59%
Total	**815.19**	**100.00%**	**505.50**	**309.69**		**309.69**	100.00%

The Unutilized Net Proceeds are expected to be utilized by the end of 2026.

Reasons for the Change in Use of Net Proceeds

The reasons for the above changes in the proposed applications of the Net Proceeds and the reallocation of the Unutilized Net Proceeds are as follows:

- From the time of the Listing in November 2020, the Company's business has been focused on developing, manufacturing and commercializing cell-based immunotherapies for hematological cancers, autoimmune disease and solid tumors.

- Since 2020, in the hematology field, the Company has brought relma-cel to commercialization as a third-line treatment for LBCL, r/r FL and r/r MCL and the Company has (a) driven commercialization of relma-cel for these indications; (b) submitted an NDA application in May 2025 for Carteyva® as a second-line therapy for transplant-ineligible patients with r/r LBCL; and (c) developed a vector manufacturing platform which has successfully produced lentiviral vectors for the manufacture of Carteyva®.

- The Company's research and development team (the "**R&D team**") is actively engineering innovative pipeline products leveraging its developmental capabilities and know-how. One of our first in-house developed products is JWCAR201, a dual targeting autologous CAR-T cell therapy designed for B-cell malignancies and autoimmune diseases. By incorporating dual targeting, this product is expected to have a broader range of effectiveness, increase the signaling threshold, and significantly reduce the risk of relapse due to antigen downregulation or loss, a common phenomenon observed in hematological cancers. Additionally, we plan to equip this product with enhanced Armored elements to improve performance and shield it from suppressive factors produced by the tumor's defense systems. Our next generation processing techniques will be deployed to manufacture this product, aiming to deliver a more potent, rapid, and cost-effective therapy. Both products are intended for commercialization both within and outside China. The Company has also determined that it is appropriate to allocate a portion of the Unutilized Net Proceeds to fund product discovery activities carried out by the R&D team to develop new therapy areas.

- In addition, we continue to explore innovative approaches to simplify the manufacturing process. We are investigating the feasibility of short process and non-viral methods that involve genomic editing and off-the-shelf CAR products for various indications. These approaches may potentially expedite the delivery of therapies to patients, improve product efficacy and safety profile, and reduce overall production costs. The Company therefore considers that reallocating an additional portion of the Unutilized Net Proceeds to the development of a set of new technologies and platforms, including optimization of manufacturing operations to potentially shorten production cycle time and exploration of new technologies for process improvement or new process platforms, will increase its profitability in the long run.

- In the solid tumor field, in October 2022, the Company established a strategic alliance with 2seventy bio to develop and commercialize a cell therapy product directed to MAGE-A4 in oncology indications. 2seventy bio's oncology and autoimmune research and development programs were acquired by Regeneron in 2024. With Regeneron's support, we believe that the Company may be able to secure a first-mover or early-mover advantage in a highly promising market through the development of such a therapy. We have established our manufacturing process for a product directed to MAGE-A4, and patient enrollment in this IIT was initiated in the first quarter of 2024.

- In 2022, the Company commenced exploration of an opportunity to develop relma-cel as a treatment for SLE, an autoimmune disease that is widely prevalent in China and is characterized by substantial unmet medical need, and in April 2023 the NMPA approved the Company's IND application relating to relma-cel as a treatment for SLE and we completed patient enrollment by the end of 2024. We have already demonstrated successful manufacture of CAR-T cells for SLE patients in both IIT/IND studies and observed a well-managed safety profile, significant improvement of clinical symptoms as well as complete depletion of B-cells. Research and development on products intended for treatment of autoimmune diseases including SLE remains an important priority for the Company.

- Historically the Company primarily accessed discovery capabilities through its relationships with counterparties such as Juno and 2seventy bio. Going forward, the Company will continue to enhance its own in-house product discovery capability while also taking advantage of appropriate opportunities to collaborate with counterparties. The Company will continue to pursue the external collaboration opportunities for attractive and innovative assets.

In conclusion, the Company has determined that it is appropriate to revise the previous allocation of the Unutilized Net Proceeds among the following uses: (i) research and development activities relating to treatment of hematologic malignancies, autoimmune diseases and solid tumors; (ii) potential collaborations, acquisitions and in-licensing opportunities; and (iii) developing and upgrading technologies, manufacturing platform capabilities and developing new therapy areas.

Further, the Company has fully utilized the Net Proceeds originally allocated for working capital and general corporate purposes. The Company continued to execute the Group's optimization strategies in relation to its commercial initiatives, coupled with the pursuit of the organization effectiveness program. Due to improved operation efficiency, general and administrative expenses and selling expenses were reduced by 45.7% and 23.2%, respectively, for the six months ended June 30, 2025 as compared to the six months ended June 30, 2024. In order to enhance corporate cash flow and the flexibility of financial management of the Company to facilitate the growth of the Company's business and operation, the Company has resolved to reallocate HKD29.69 million, representing 9.59% of the Unutilized Net Proceeds, for working capital and general corporate purpose.

The Board has considered that, notwithstanding the change in use of the Unutilized Net Proceeds as stated above, the strategic direction of the Company is still in line with the disclosures that were made in the Prospectus. The Board confirms that there has been no material change in the nature of the Company's business as set out in the Prospectus, and the Board is of the view that the change in the use of the Net Proceeds is fair and reasonable, as this would allow the Company to deploy its financial resources more effectively to advance the pipeline products of the Company, and is therefore in the best interest of the Company and the Shareholders as a whole.

Except as disclosed above, there are no other proposed changes in the use of the Net Proceeds. The Unutilized Net Proceeds will be applied in a manner consistent with the above and remains subject to change based on the future development of market conditions and the Company's actual needs.

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at June 30, 2025, the interests and short positions of the Directors and the chief executive of the Company in the Shares, underlying Shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which had been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or which were recorded in the register required to be kept pursuant to section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

Interest in Shares and underlying Shares

Name of Director	Capacity/nature of interest	Number of shares/ underlying shares	Approximate Percentage of Shareholding in the Company[3]	Long position/ Short position/ Lending pool
Mr. Min Liu[1]	Beneficial interest	4,156,183	0.998%	Long position
Dr. Li[2]	Beneficial interest	18,623,515	4.47%	Long position
	Interest in controlled corporation	9,206,460	2.21%	Long position
Mr. Liu Cheng	Beneficial interest	5,764,582	1.38%	Long position

Notes:

(1) Mr. Min Liu held an aggregate of 3,756,183 share options and 400,000 restricted share units granted to Mr. Min Liu pursuant to the Post-IPO Share Option Scheme and the Post-IPO Restricted Share Unit Scheme, respectively. Among the 3,756,183 share options, 2,256,183 share options were granted to Mr. Min Liu on April 11, 2025. 1,500,000 share options and 400,000 restricted share units were granted to Mr. Min Liu on September 2, 2024.

(2) Dr. Li held (i) 7,500,000 Shares through his direct interests in JDI Capital Management Limited and (ii) 1,706,460 Shares through his indirect interests in Park Place Capital Management & Consulting Limited. Park Place Capital Management & Consulting Limited is wholly-owned by JDI Capital Management Limited which in turn is wholly-owned by Dr. Li.

As at June 30, 2025, Dr. Li is interested in a total of 18,623,515 underlying Shares in the Company, which comprises 14,605,766 Restricted Share Units granted to him pursuant to the Restricted Share Unit Scheme and 4,017,749 share options granted to him pursuant to the Post-IPO Incentivization Scheme.

Accordingly, Dr. Li is interested in an aggregate of 27,829,975 Shares in the Company.

(3) The calculation is based on the total number of 416,232,634 Shares in issue as at June 30, 2025.

Save as disclosed above, as at June 30, 2025, none of the Directors or the chief executive of the Company had or was deemed to have any interest or short position in the Shares, underlying Shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) that was required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or required to be recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise disclosed in this report, at no time during the Reporting Period was the Company or any of its subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2025, to the best knowledge of the Directors, the following persons (not being a Director or chief executive of the Company) had interests or short positions in the Shares or underlying Shares which fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or as recorded in the register required to be kept by the Company pursuant to section 336 of the SFO:

Name of Shareholder	Capacity/Nature of interest	Number of Shares/ underlying Shares	Approximate Percentage of Shareholding in the Company[2]	Long Position/ Short Position/ Lending Pool
Juno[1]	Beneficial interest	70,231,140	16.87%	Long position
Celgene Corporation[1]	Interest in controlled corporation	70,231,140	16.87%	Long position
BMS[1]	Interest in controlled corporation	70,231,140	16.87%	Long position

Notes:

(1) As at June 30, 2025, Juno directly held 70,231,140 Shares. Pursuant to the BCMA License Agreement, the 4,665,530 Juno Settlement Shares may be issued to Juno upon exercise of the second warrant as part of the second upfront payment in relation to Juno's orva-cel. In February 2021, BMS announced that it would discontinue clinical development of orva-cel and therefore, the 4,665,530 Juno Settlement Shares shall no longer be issued to Juno. Juno is wholly-owned by Celgene which is in turn wholly-owned by BMS. As such, under the SFO, BMS (through its interest in a controlled corporation) is deemed to be interested in 70,231,140 Shares held by Juno.

(2) The calculation is based on the total number of 416,232,634 Shares in issue as at June 30, 2025.

Save as disclosed above, as at June 30, 2025, the Directors were not aware of any persons (who were not Directors or chief executive of the Company) who had an interest or short position in the Shares or underlying Shares of the Company which would fall to be disclosed under Divisions 2 and 3 of Part XV of the SFO, or which would be required, pursuant to Section 336 of the SFO, to be entered in the register referred to therein.

SHARE INCENTIVIZATION SCHEMES

Pre-IPO Incentivization Scheme

Our Company adopted the Pre-IPO Incentivization Scheme on September 4, 2019. The purpose of the Pre-IPO Incentivization Scheme is to attract, retain and motivate employees, Directors and such other eligible persons and to provide a means of compensating them through the grant of options for their contribution to the growth and profits of the Group, and to allow such employees, directors and other persons to participate in the growth and profitability of the Group.

Options granted generally vest over a four-year period from the date of grant. There are two types of vesting schedules: (i) with 30% of total options vesting on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; and (ii) with 25% of total options vesting on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

Participants of the Pre-IPO Incentivization Scheme include any employee or Directors (executive, non-executive and independent non-executive Director) of the Company or any of its subsidiaries and any other service provider to the Group, who in the sole opinion of the Board, will contribute or have contributed to the Group. The maximum entitlement for each participant is that the total number of Shares issued and to be issued upon exercise of the options granted to each participant (including both exercised, cancelled and outstanding options) in any 12-month period shall not exceed 1% of the total number of Shares in issue (the "**Individual Limit**"). Any further grant of options to any one participant in excess of the Individual Limit shall be subject to the Shareholders' approval in general meeting with such participant and his associates abstaining from voting.

The options under the Pre-IPO Incentivization Scheme were granted to the grantees at nil consideration. An option may be exercised in accordance with the terms of the Pre-IPO Incentivization Scheme at any time for a period of 10 years after the date of grant of the option for each corresponding grantee as set out in their respective offer letters.

As of January 1, 2025 and June 30, 2025, the total number of share options available for grant under the scheme mandates of the Pre-IPO Incentivization Scheme was 1,438,704. The Pre-IPO Incentivization Scheme does not have a service provider sublimit. As at the date of this interim report, the total number of shares available for issue under the Pre-IPO Incentivization Scheme was 1,438,704, representing approximately 0.14% of the total Shares in issue (excluding treasury Shares).

The Pre-IPO Incentivization Scheme has a remaining term of approximately three years and eleven months as of the date of this report.

Details of options granted under the Pre-IPO Incentivization Scheme during the Reporting Period is as follows:

Name of Participant or Category of Participant	Date of grant	Number of outstanding options held at January 1, 2025	Number of options granted	Number of options lapsed	Number of options cancelled	Number of options exercised	Number of outstanding options held at June 30, 2025	Exercise Period[1]	Vesting Period[2]	Exercise Price *(HKD)*	Weighted average closing price of the shares immediately before the dates on which the options were exercised *(HKD)*	Fair value of options at the date of grant *(USD)*
Other employee participants	04-09-2019	576,930	—	286,100	—	138,330	152,500	10 years	4 years	0.775	1.61	0.63
	04-09-2019	220,140	—	—	—	—	220,140	10 years	4 years	5.07625	—	0.33
	30-06-2020	425,800	—	146,780	—	72,380	206,640	10 years	4 years	0.000775	2.05	1.92
	10-09-2020	—	—	—	—	—	—	10 years	4 years	0.000078	—	2.43
Other Related Entity Participants						N/A						
Other Service Providers						N/A						

Notes:

(1) An option may be exercised in accordance with the terms of the Pre-IPO Incentivization Scheme at any time for a period of 10 years from the date of grant for each corresponding grantee as set out in their respective offer letters.

(2) Options granted generally vest over a four-year period from the date of grant. The options shall vest in accordance with either of these vesting schedules: (i) with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; or (ii) with 25% of total options shall vest on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

(3) All options granted under the Pre-IPO Incentivization Scheme were not subject to any performance targets.

(4) The options under the Pre-IPO Incentivization Scheme were granted to the grantees at nil consideration.

(5) The closing price of the Shares immediately before the dates on which the options were granted was not applicable as the Company was not yet listed on the dates of grant.

(6) During the Reporting Period, the number of Shares that may be issued in respect of the options granted under the Pre-IPO Incentivization Scheme divided by the weighted average number of total Shares in issue was approximately 0.14%.

(7) During the Reporting Period, no grants were made to any eligible participants of the Pre-IPO Incentivization Scheme with options granted or to be granted in excess of the 1% individual limit and no grants were made to any related entity participants or service providers with options granted or to be granted in any 12-month period exceeding 0.1% of the relevant class of shares in issue (excluding treasury shares) of the Company.

(8) For details of the basis of measurement for the fair value of options granted, please refer to note 24 headed "Share-based payments" of the condensed consolidated financial statements.

Post-IPO Incentivization Scheme

Our Company adopted the Post-IPO Incentivization Scheme on October 14, 2020. The purpose of the Post-IPO Incentivization Scheme is to enable our Group to grant options to selected participants as incentives or rewards for their contribution to our Group.

Options granted generally vest over a four-year period from the date of grant. There are two types of vesting schedules: (i) with 30% of total options vesting on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; and (ii) with 25% of total options vesting on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

The options under the Post-IPO Incentivization Scheme were granted to the grantees at nil consideration. An option may be exercised in accordance with the terms of the Post-IPO Incentivization Scheme at any time for a period of ten years after the date of grant of the option for each corresponding grantee as set out in their respective offer letters. The date of board meeting for proposing any grant of options under the Post-IPO Incentivization Scheme should be taken as the date of grant for the purpose of calculating the exercise price pursuant to Rule 17.03E of the Listing Rules.

Participants of the Post-IPO Incentivization Scheme include any employee or any Directors (including executive, non-executive and independent non-executive directors) of the Company or any of its subsidiaries and any other service provider to the Group, who in the sole opinion of the Board, will contribute or have contributed to the Group. The maximum entitlement for any one participant is that the total number of Shares issued and to be issued upon exercise of the options granted to each participant (including both exercised, cancelled and outstanding options) in any 12-month period shall not exceed the Individual Limit. Any further grant of options to any one participant in excess of the Individual Limit shall be subject to the Shareholders' approval in general meeting with such participant and his associates abstaining from voting.

As of January 1, 2025 and June 30, 2025, the total number of share options available for grant under the scheme mandates of the Post-IPO Incentivization Scheme was 26,696,490 and 18,552,567, respectively. The Post-IPO Incentivization Scheme does not have a service provider sublimit. As at the date of this interim report, the total number of shares available for issue under the Post-IPO Incentivization Scheme was 18,552,567, representing approximately 3.72% of the total Shares in issue (excluding treasury Shares).

The Post-IPO Incentivization Scheme has a remaining term of approximately five years and one month as of the date of this report.

With respect to the 1,500,000 options granted to Mr. Min Liu, an executive Director of the Company, on September 2, 2024, a time-based vesting schedule is applicable to the options granted with no performance target attached. The options granted will give Mr. Liu an opportunity to have a personal stake in the Company and will help motivate him in optimizing his performance and efficiency. The number of options granted is based on the potential of Mr. Liu and no additional performance target is imposed before the options are vested to Mr. Liu. In view of the above and in line with the customary practice of the Company in terms of equity based remuneration, the Remuneration Committee considered the grant of options to be in alignment with the purposes of the Post-IPO Incentivization Scheme.

With respect to the 2,256,183 options granted to Mr. Min Liu, Chairman and an executive Director of the Company, on April 11, 2025, 256,183 options were granted with no performance target attached and shall immediately vest on the date of grant. The Board and the Remuneration Committee are of the view that, taking into account of (i) having reviewed the Company's overall performance, the grant of 256,183 options to Mr. Liu serves as recognition of Mr. Liu's role with the Group and contribution to the development and growth of the Group for the preceding fiscal year; (ii) the remuneration of Mr. Liu includes the grant of options as part of his remuneration package; and (iii) Mr. Liu's remuneration package has been reviewed by the Remuneration Committee to be in line with the industry practice, the grant of 256,183 options to Mr. Liu with no performance target attached and shall immediately vest on the date of grant reinforces Mr. Liu's commitment to the Group and thus aligns with the purposes of the Post-IPO Incentivization Scheme.

With regard to the remaining 2,000,000 options granted to Mr. Liu, the relevant number of options shall commence vesting 6 months from each of the respective dates upon Mr. Liu's fulfilment of the respective performance targets. For details, see note (7) in the table below.

Details of options granted under the Post-IPO Incentivization Scheme during the Reporting Period is as follows:

Name of Participant or Category of Participant	Date of grant	Closing price of shares immediately before the date on which the options were granted *(HKD)*	Number of outstanding options held at January 1, 2025	Number of options granted	Number of options lapsed	Number of options cancelled	Number of options exercised	Number of outstanding options held at June 30, 2025	Exercise Period[1]	Vesting Period	Exercise Price *(HKD)*	Weighted average closing price of the shares immediately before the dates on which the options were exercised *(HKD)*	Fair value of options at the date of grant *(HKD)*
Director													
Mr. Liu, Chairman and executive Director	02–09–2024	1.34	1,500,000	–	–	–	–	1,500,000	10 years	4 years[3]	1.32	–	0.62
	11-04-2025	1.44	–	2,256,183	–	–	–	2,256,183	10 years	4 years[7]	1.48	–	1.00
Dr. Li, non-executive Director	30–09–2021	14.74	4,017,749	–	–	–	–	4,017,749	10 years	4 years[2]	–	–	6.928
Other employee participants	30-09-2021	14.74	1,457,021	–	588,888	–	–	868,133	10 years	4 years[2]	16.2	–	6.928/7.836
	17-12-2021	11.36	257,618	–	–	–	–	257,618	10 years	4 years[3]	11.992	–	5.472/5.779
	24-06-2022	8.26	856,977	–	334,075	–	–	522,902	10 years	4 years[2]	8.94	–	4.588/4.818
	29-09-2022	3.25	6,667	–	–	–	–	6,667	10 years	4 years[3]	3.31	–	1.578/1.676
	16-12-2022	4.34	30,000	–	5,000	–	–	25,000	10 years	4 years[3]	4.83	–	2.058/2.194
	29-08-2023	6.35	277,007	–	141,227	–	1,284	134,496	10 years	4 years[2][5]	2.46	3.01	1.54/1.57
	02-09-2024	1.34	539,144	–	539,144	–	–	–	10 years	4 years[3][6]	1.32	–	0.57
	06-01-2025	1.27	–	387,740	–	–	–	387,740	10 years	4 years[2][8]	1.36	–	0.94
	11-04-2025	1.44	–	5,500,000	–	–	–	5,500,000	10 years	4 years[2][9]	1.48	–	0.87
Other Related Entity Participants							N/A						
Other Service Providers							N/A						

Notes:

(1) An option may be exercised in accordance with the terms of the Post-IPO Incentivization Scheme at any time for a period of ten years after the date of grant of the option for each corresponding grantee as set out in their respective offer letters.

(2) Options granted generally vest over a four-year period from the date of grant. The options shall vest in accordance with either of these vesting schedules: (i) with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; or (ii) with 25% of total options shall vest on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

(3) Options granted generally vest over a four-year period from the date of grant, with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively.

(4) All options granted under the Post-IPO Incentivization Scheme prior to August 29, 2023 were not subject to any performance targets.

(5) The vesting of the options granted to other employee participants (the "**Grantees**") on August 29, 2023 is conditional upon the Grantees having fulfilled certain performance targets and other requirements as set out in the option letters entered into between the Company and the Grantees. Such performance targets include the Grantees' individual appraisal results with respect to the relevant vesting period. The options granted will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested options of the corresponding vesting period shall automatically lapse.

(6) The vesting of the options granted to an employee participant (the "**Grantee**") on September 2, 2024 is conditional upon the Grantee having fulfilled certain performance targets and other requirements as set out in the option letters entered into between the Company and the Grantee. Such performance targets include the Grantee's individual appraisal results with respect to the relevant vesting period. The options granted will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested options of the corresponding vesting period shall automatically lapse.

(7) With regard to the 2,000,000 options among the 2,256,183 options granted to Mr. Liu, Chairman and an executive Director, on April 11, 2025, the relevant number of options shall commence vesting 6 months from each of the respective dates upon Mr. Liu's fulfilment of the respective performance targets. The respective vesting commencement dates shall be as follows:

- 100,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by December 31, 2025
- 200,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by December 31, 2026
- 200,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by June 30, 2026
- 200,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by March 31, 2026
- 200,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by October 10, 2034
- 700,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by June 30, 2026
- 400,000 options shall commence vesting 6 months from the date of fulfilment of certain performance targets by June 30, 2026

Notwithstanding the foregoing, if Mr. Liu fulfils a specific performance target (such fulfilment to be determined by the Board in its sole discretion) on any date since the date of grant by October 10, 2034, all options not previously vested pursuant to one or more of the respective performance targets mentioned above shall commence vesting 6 months from the date on which such specific performance target has been fulfilled.

The Remuneration Committee acknowledges that certain vesting periods of the 2,000,000 options granted to Mr. Liu maybe less than 12 months from the date of grant. Having considered that, (i) the respective vesting commencement dates are tied to the dates on which Mr. Liu fulfils the respective performance targets and (ii) Mr. Liu's performance and contribution to the Group to date and his potential, the Remuneration Committee is of the view that permitting such a circumstance in having vesting periods of less than 12 months could effectively incentivize Mr. Liu in further optimizing his performance and efficacy to achieve the respective performance targets pursuant to the grant for the benefit and growth of the Group, and that such arrangement to be in alignment with the purposes of Post-IPO Incentivization Scheme.

(8) The vesting of the options granted to other employee participants (the "**Grantees**") on January 6, 2025 is conditional upon the Grantees having fulfilled certain performance targets and other requirements as set out in the option letters entered into between the Company and the Grantees. Such performance targets include the Grantees' individual appraisal results with respect to the relevant vesting period. The options granted will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested options of the corresponding vesting period shall automatically lapse.

(9) The vesting of the options granted to other employee participants (the "**Grantees**") on April 11, 2025 is conditional upon the Grantees having fulfilled certain performance targets and other requirements as set out in the option letters entered into between the Company and the Grantees. Such performance targets include the Grantees' individual appraisal results with respect to the relevant vesting period. The options granted will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested options of the corresponding vesting period shall automatically lapse.

(10) During the Reporting Period, the number of Shares that may be issued in respect of options granted under the Post-IPO Incentivization Scheme divided by the weighted average number of total Shares in issue was approximately 3.72%.

(11) During the Reporting Period, no grants were made to any eligible participants of the Post-IPO Incentivization Scheme with options granted or to be granted in excess of the 1% individual limit and no grants were made to any related entity participants or service providers with options granted or to be granted in any 12-month period exceeding 0.1% of the relevant class of shares in issue (excluding treasury shares) of the Company.

(12) For details of the basis of measurement for the fair value of options granted, please refer to note 24 headed "Share-based payments" of the condensed consolidated financial statements.

Pre-IPO Restricted Share Unit Scheme and Post-IPO Restricted Share Unit Scheme (the "Restricted Share Unit Schemes")

Our Company adopted the Pre-IPO Restricted Share Unit Scheme on September 4, 2019 and the Post-IPO Restricted Share Unit Scheme on October 14, 2020. The purpose of the Restricted Share Unit Schemes is to attract, retain and motivate employees, Directors and such other eligible persons and to provide a means of compensating them through the grant of RSUs for their contribution to the growth and profits of the Group, and to allow such employees, directors and other persons to participate in the growth and profitability of the Group.

RSUs granted generally vest over a four-year period from the date of grant. There are two types of vesting schedules: (i) with 30% of total options vesting on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; and (ii) with 25% of total options vesting on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively. The RSUs under the Restricted Share Unit Schemes were granted to the grantees at nil consideration and were or will be transferred to the grantees upon vesting at nil consideration.

Participants of the Restricted Share Unit Schemes include any employee or any Directors (executive, non-executive and independent non-executive Director) of the Company or any of its subsidiaries and any other service provider to the Group, who in the sole opinion of the Board, will contribute or have contributed to the Group. The maximum entitlement for each participant is that the total number of Shares issued and to be issued upon exercise of the RSUs granted to each participant (including both exercised, cancelled and outstanding options) in any 12-month period shall not exceed the Individual Limit. Any further grant of RSUs to any one participant in excess of the Individual Limit shall be subject to the Shareholders' approval in general meeting with such participant and his associates abstaining from voting.

As of January 1, 2025 and June 30, 2025, the total number of RSUs available for grant under the Pre-IPO Restricted Share Unit Scheme was 1,438,704 and the Post-IPO Restricted Share Unit Scheme was 3,382,363 and 3,304,815, respectively. As at the date of this interim report, the total number of shares available for issue under the Pre-IPO Restricted Share Unit Scheme and the Post-IPO Restricted Share Unit Scheme were 1,438,704 and 3,304,815, representing approximately 0.18% and 0.40% of the total Shares in issue (excluding treasury Shares), respectively.

The Pre-IPO Restricted Share Unit Scheme and the Post-IPO Restricted Share Unit Scheme will remain in force for a period of ten years unless terminated sooner, and has a remaining term of approximately three years and eleven months and five years and one month, respectively, as of the date of this interim report.

With respect to the RSUs granted to Mr. Liu, chairman and an executive Director of the Company, on September 2, 2024, a time-based vesting schedule is applicable to the RSUs granted with no performance target attached. The RSUs granted will give Mr. Liu an opportunity to have a personal stake in the Company and will help motivate him in optimizing his performance and efficiency. The number of RSUs granted is based on the potential of Mr. Liu and no additional performance target is imposed before the RSUs are vested to Mr. Liu. In view of the above and in line with the customary practice of the Company in terms of equity-based remuneration, the Remuneration Committee considered the grant of RSUs are in alignment with the purposes of the Post-IPO Restricted Share Unit Scheme.

Details of RSUs granted under the Pre-IPO Restricted Share Unit Scheme during the Reporting Period are as follows:

Name of Participant or Category of Participant	Date of grant	Number of outstanding RSUs held at January 1, 2025	Number of RSUs granted	Number of RSUs lapsed	Number of RSUs cancelled	Number of RSUs vested	Number of outstanding RSUs held at June 30, 2025	Exercise Period[4]	Vesting Period[2]	Purchase Price	Weighted average closing price of the shares immediately before the dates on which the RSUs were vested *(HKD)*	Fair value of RSUs at the date of grant *(USD)*
Directors												
Dr. Li, non-executive Director	30-06-2020	761,440	–	–	–	–	761,440	N/A	4 years	Nil	–	1.92
Other employee participants	30-06-2020	–	–	–	–	–	–	N/A	4 years	Nil	2.33	1.92
	10-09-2020	–	–	–	–	–	–	N/A	4 years	Nil	1.89	2.43
Other Related Entity Participants						N/A						
Other Service Providers						N/A						

Notes:

(1) The closing prices of Shares immediately before the dates on which the RSUs were granted under the Pre-IPO Restricted Share Unit Scheme was not applicable as the Company was not yet listed on the dates of grant.

(2) RSUs granted generally vest over a four-year period from the date of grant. The RSUs shall vest in accordance with either of these vesting schedules: (i) with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; or (ii) with 25% of total options shall vest on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

(3) All RSUs granted under the Pre-IPO Restricted Share Unit Scheme were not subject to any performance targets.

(4) Exercise period is not applicable to RSUs.

(5) During the Reporting Period, the number of Shares that may be issued in respect of RSUs granted under the Pre-IPO Restricted Share Unit Scheme divided by the weighted average number of total Shares in issue was approximately 0.18%.

(6) During the Reporting Period, no grants were made to any eligible participants of the Pre-IPO Restricted Share Unit Scheme with RSUs granted or to be granted in excess of the 1% individual limit and no grants were made to any related entity participants or service providers with RSUs granted or to be granted in any 12-month period exceeding 0.1% of the relevant class of shares in issue (excluding treasury shares) of the Company.

(7) For details of the basis of measurement for the fair value of RSUs granted, please refer to note 24 headed "Share-based payments" of the condensed consolidated financial statements.

Details of RSUs granted under the Post-IPO Restricted Share Unit Scheme during the Reporting Period are as follows:

Name of Participant or Category of Participant	Date of grant	Closing price of shares immediately before the date on which the RSUs were granted *(HKD)*	Number of outstanding RSUs held at January 1, 2025	Number of RSUs granted	Number of RSUs lapsed	Number of RSUs cancelled	Number of RSUs vested	Number of outstanding RSUs held at June 30, 2025	Exercise Period[8]	Vesting Period	Purchase price	Weighted average closing price of the shares immediately before the dates on which the RSUs were vested *(HKD)*	Fair value of RSUs at the date of grant *(HKD)*
Director													
Mr. Liu, Chairman and executive Director	02-09-2024	1.34	400,000	–	–	–	–	400,000	N/A	4 years[2]	Nil	–	1.28
Dr. Li, non-executive Director	30-09-2021	14.74	1,008,574	–	–	–	–	1,008,574	N/A	4 years[1]	Nil	–	14.92
Other employee participants	30-09-2021	14.74	113,168	–	5,186	–	100,208	7,774	N/A	4 years[1]	Nil	1.68	14.92
	17-12-2021	11.36	39,581	–	–	–	–	39,581	N/A	4 years[2]	Nil	–	11.48
	24-06-2022	8.26	177,590	–	34,314	–	75,851	67,425	N/A	4 years[1]	Nil	1.75	8.94
	29-09-2022	3.25	4,667	–	–	–	2,000	2,667	N/A	4 years[2]	Nil	1.76	3.18
	16-12-2022	4.34	17,500	–	–	–	–	17,500	N/A	4 years[2]	Nil	–	4.25
	29-08-2023	6.35	93,888	–	30,838	–	–	63,050	N/A	4 years[1][4]	Nil	–	2.46
	02-09-2024	1.34	269,572	–	269,572	–	–	–	N/A	4 years[5]	Nil	–	1.28
	06-01-2025	1.27	–	77,548	–	–	–	77,548	N/A	4 years[2][6]	Nil	–	1.36
Other Related Entity Participants							N/A						
Other Service Providers							N/A						

Notes:

(1) RSUs granted generally vest over a four-year period from the date of grant. The RSUs shall vest in accordance with either of these vesting schedules: (i) with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; or (ii) with 25% of total options shall vest on the first anniversary of the vesting commencement date and the remaining 25%, 25% and 25% shall vest on the second anniversary, third anniversary and fourth anniversary of the vesting commencement date, respectively.

(2) RSUs granted generally vest over a four-year period from the date of grant, with 30% of total options shall vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% shall vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively.

(3) All RSUs granted under the Post-IPO Restricted Share Unit Scheme prior to August 29, 2023 were not subject to any performance targets.

(4) The vesting of the RSUs granted to the other employee participants (the "**Grantees**") on August 29, 2023 is conditional upon the Grantees having fulfilled certain performance targets and other requirements as set out in the award agreements entered into between the Company and the Grantees. Such performance targets include the Grantees' individual appraisal results with respect to the relevant vesting period. The RSUs will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested RSUs of the corresponding vesting period shall automatically lapse.

(5) With respect to the RSUs granted to an employee participant (the "**Grantee**") on September 2, 2024, the vesting of the RSUs granted is conditional upon the Grantee having fulfilled certain performance targets and other requirements as set out in the award agreement entered into between the Company and the Grantee. Such performance targets include the Grantee's individual appraisal results with respect to the relevant vesting period. The RSUs will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested RSUs of the corresponding vesting period shall automatically lapse.

(6) With respect to the RSUs granted to two employee participants (the "**Grantees**") on January 6, 2025 the vesting of the RSUs granted is conditional upon the Grantees having fulfilled certain performance targets and other requirements as set out in the award agreement entered into between the Company and the Grantees. Such performance targets include the Grantees' individual appraisal results with respect to the relevant vesting period. The RSUs will only be vested if the Grantee passes his or her respective performance evaluation for the fiscal year preceding the corresponding vesting period. If the Grantee fails to achieve, the unvested RSUs of the corresponding vesting period shall automatically lapse.

(7) During the Reporting Period, the number of Shares that may be issued in respect of RSUs granted under the Post-IPO Restricted Share Unit Scheme divided by the weighted average number of total Shares in issue was approximately 0.41%.

(8) During the Reporting Period, no grants were made to any eligible participants of the Post-IPO Restricted Share Unit Scheme with RSUs granted or to be granted in excess of the 1% individual limit and no grants were made to any related entity participants or service providers with RSUs granted or to be granted in any 12-month period exceeding 0.1% of the relevant class of shares in issue (excluding treasury shares) of the Company.

(9) Exercise period is not applicable to RSUs.

(10) For details of the basis of measurement for the fair value of RSUs granted, please refer to note 24 headed "Share-based payments" of the condensed consolidated financial statements.

SIGNIFICANT LEGAL PROCEEDINGS

For the six months ended June 30, 2025, the Company has not engaged in any litigation or arbitration of material importance and no litigation or claim of material importance is known to the Directors to be pending or threatening against the Company.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

Save as disclosed in this report, the Group does not have other future plans for material investments and capital assets at present.

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the six months ended 30 June 2025

	NOTES	Six months ended 30 June	
		2025	2024
		RMB'000	*RMB'000*
		(Unaudited)	(Unaudited)
Revenue	*4*	**106,346**	86,815
Cost of sales		**(41,229)**	(43,070)
Gross profit		**65,117**	43,745
Other income	*5*	**4,282**	1,884
Other gains and losses	*6*	**(160,116)**	(6,729)
Selling expenses		**(58,494)**	(76,172)
General and administrative expenses		**(32,190)**	(59,233)
Research and development expenses		**(92,041)**	(151,008)
Finance income	*7*	**12,423**	13,299
Finance costs	*7*	**(6,246)**	(6,053)
Finance costs — net	*7*	**6,177**	7,246
Loss before tax	*8*	**(267,265)**	(240,267)
Income tax expense	*9*	**—**	—
Loss for the period		**(267,265)**	(240,267)
Other comprehensive (expense) income			
Items that will not be reclassified to profit or loss:			
Exchange differences arising on translation from functional currency to presentation currency	*24*	**(1,158)**	15,829
Items that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations	*24*	**3,228**	3,719
Other comprehensive income for the period		**2,070**	19,548
Total comprehensive expense for the period		**(265,195)**	(220,719)
LOSS PER SHARE			
— Basic and diluted *(RMB)*	*11*	**(0.64)**	(0.58)

Condensed Consolidated Statement of Financial Position

As at 30 June 2025

	NOTES	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Non-Current Assets			
Property, plant and equipment		**207,488**	232,392
Right-of-use assets		**32,784**	41,488
Intangible assets	*12*	**417,539**	582,966
Prepayment for license	*13*	**7,159**	7,189
Other non-current assets	*14*	**7,426**	7,656
		672,396	871,691
Current Assets			
Inventories	*15*	**67,021**	31,257
Trade receivables	*16*	**25,055**	—
Other receivables and prepayments	*17*	**3,682**	7,233
Other current assets	*18*	**4,407**	12,808
Bank balances and cash		**646,880**	757,375
		747,045	808,673
Current Liabilities			
Trade and other payables	*19*	**105,252**	70,481
Borrowings	*20*	**320,513**	361,634
Lease liabilities		**11,463**	14,625
Contract liabilities	*21*	**29,436**	16,207
Other current liabilities		**3,685**	2,107
		470,349	465,054
Net Current Assets		**276,696**	343,619
Total Assets Less Current Liabilities		**949,092**	1,215,310

Condensed Consolidated Statement of Financial Position

As at 30 June 2025

	NOTES	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Capital and Reserves			
Share capital	22	**27**	27
Reserves	23	**6,731,804**	6,725,096
Accumulated losses		**(5,823,223)**	(5,555,958)
Total Equity		**908,608**	1,169,165
Non-Current Liabilities			
Borrowings	20	**19,300**	19,500
Lease liabilities		**21,184**	26,645
		40,484	46,145
		949,092	1,215,310

Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2025

	Attributable to owners of the Company			
	Share capital *RMB'000*	Reserves *RMB'000 (Note 24)*	Accumulated losses *RMB'000*	Total *RMB'000*
At 1 January 2024 (Audited)	27	6,649,145	(4,965,334)	1,683,838
Loss for the period	—	—	(240,267)	(240,267)
Other comprehensive income for the period	—	19,548	—	19,548
Total comprehensive income (expense) for the period	—	19,548	(240,267)	(220,719)
Issuance of ordinary shares *(Note 22)*	*	268	—	268
Issuance of treasury shares hold in the trust *(Note 22)*	*	*	—	*
Recognition of share-based compensation expenses *(Note 24)*	—	18,557	—	18,557
At 30 June 2024 (Unaudited)	27	6,687,518	(5,205,601)	1,481,944
At 1 January 2025 (Audited)	**27**	**6,725,096**	**(5,555,958)**	**1,169,165**
Loss for the period	**—**	**—**	**(267,265)**	**(267,265)**
Other comprehensive income for the period	**—**	**2,070**	**—**	**2,070**
Total comprehensive income (expense) for the period	**—**	**2,070**	**(267,265)**	**(265,195)**
Issuance of ordinary shares *(Note 22)*	*****	**102**	**—**	**102**
Issuance of treasury shares hold in the trust *(Note 22)*	*****	*****	**—**	*****
Recognition of share-based compensation expenses *(Note 24)*	**—**	**4,536**	**—**	**4,536**
At 30 June 2025 (Unaudited)	**27**	**6,731,804**	**(5,823,223)**	**908,608**

* Amount is less than RMB1,000

Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2025

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
OPERATING ACTIVITIES		
Operating cash flows before movements in working capital	**(54,331)**	(161,770)
Increase in inventories	**(37,262)**	(15,829)
Increase in trade receivables	**(25,055)**	—
Decrease in other receivables and prepayments	**3,551**	4,848
Decrease/(increase) in other current assets	**8,401**	(2,776)
Decrease in other non-current assets	**230**	10,899
Increase/(decrease) in trade and other payables	**34,771**	(15,092)
Increase/(decrease) in contract liabilities	**13,229**	(7,266)
Increase/(decrease) in other current liabilities	**1,578**	(1,218)
Cash used in operations	**(54,888)**	(188,204)
NET CASH USED IN OPERATING ACTIVITIES	**(54,888)**	(188,204)
INVESTING ACTIVITIES		
Purchases of property, plant and equipment	**(251)**	(2,869)
Purchases of intangible assets	**(108)**	(10,075)
NET CASH USED IN INVESTING ACTIVITIES	**(359)**	(12,944)
FINANCING ACTIVITIES		
Proceeds from issue of ordinary shares	**102**	268
Proceeds from borrowings	**74,368**	135,000
Repayments of borrowings	**(116,600)**	(63,900)
Interest paid for borrowings	**(4,543)**	(4,955)
Repayment of lease liabilities	**(6,644)**	(8,292)
Interest paid for lease liabilities	**(791)**	(1,069)
NET CASH (USED IN)/FROM FINANCING ACTIVITIES	**(54,108)**	57,052
Effect of foreign exchange rate changes	**(1,140)**	7,221
NET DECREASE IN CASH AND CASH EQUIVALENTS	**(110,495)**	(136,875)
Cash and cash equivalents at beginning of the period	**757,375**	1,005,909
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	**646,880**	869,034

1. GENERAL INFORMATION AND BASIS OF PREPARATION

JW (Cayman) Therapeutics Co. Ltd (the "**Company**") was incorporated in the Cayman Islands, with its registered office situate at the offices of Maples Corporate Services Limited, PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, on September 6, 2017 as an exempted company with limited liability.

The Company and its subsidiaries, hereinafter collectively referred to as the "**Group**" are primarily engaged in research and development ("**R&D**"), manufacturing, marketing of cellular immunotherapy products in the People's Republic of China (the "**PRC**") and license of know-how.

The Company's shares began to list on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on November 3, 2020 (the "**Listing**").

The condensed consolidated financial statements are presented in Renminbi ("**RMB**"), which is different from the Company's functional currency of United States dollars ("**USD**").

In addition, the condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("**IASB**") as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on the Stock Exchange.

Going concern assessment

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis.

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to a IFRS Accounting Standard issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2025 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IAS 21	Lack of Exchangeability

The application of the amendments to a IFRS Accounting Standard in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. SEGMENT INFORMATION

The executive directors of the Company, being the chief operating decision maker ("**CODM**"), reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole. The Group has only one reportable segment. Hence, no further information other than entity wide information was presented.

No analysis of the Group's assets and liabilities by operating segments is disclosed as it is not regularly provided to the CODM for review.

Except for the revenue generated from grant of a non-exclusive license as disclosed in Note 4 and Note 26 is attributed to the Company, all the revenue from external customers is attributed to the Group and derived from the PRC. All non-current assets except in-licenses recognised as intangible assets of the Group are all located in the PRC.

There is no customer contributing over 10% of the total revenue of the Group for the six months ended 30 June 2025 and 2024, except for the transactions with a related party set out in Note 4 and Note 26.

4. REVENUE

Disaggregation of revenue from contracts with customers is as follows:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from sales of autologous chimeric antigen receptor T-cell immunotherapy products — at point in time	**81,239**	86,815
Revenue from grant of a non-exclusive license *(Note 25)* — at point in time	**25,107**	—
	106,346	86,815

5. OTHER INCOME

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Government grants — cost related *(Note)*	**4,282**	1,884

Note: The government grants and subsidies related to funding received to compensate for the Group's research and development expenses. Some of the grants received are related to future costs expected to be incurred and require the Group to comply with conditions attached to the grants and the government to acknowledge the compliance of these conditions. When the required conditions set by the government for such grants are met, the proportion of the qualified funds is recognised as "Other income" and the remaining balance is recorded as "Trade and other payables — deferred income".

6. OTHER GAINS AND LOSSES

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Impairment loss on intangible assets	**(152,602)**	—
Net foreign exchange losses	**(6,800)**	(6,998)
Others	**(714)**	269
	(160,116)	(6,729)

7. FINANCE COSTS

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Interest income from bank balances	**12,423**	13,299
Interest expense on bank borrowings	**(5,455)**	(4,984)
Interest expense on lease liabilities	**(791)**	(1,069)
	6,177	7,246

8. LOSS BEFORE TAX

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss before tax has been arrived after charging:		
Directors' emoluments	**829**	875
Wages and salaries	**53,523**	85,902
Share-based compensation expenses	**4,536**	18,557
Other post-employment benefits	**13,263**	20,691
Termination benefits	**2,381**	1,956
Total staff costs (including directors' emoluments)	**74,532**	127,981
Capitalised in inventories	**(5,083)**	(4,688)
	69,449	123,293
Depreciation of property, plant and equipment	**25,155**	29,210
Depreciation of right-of-use assets	**6,724**	8,242
Amortization of intangible assets	**9,314**	9,437
Total depreciation and amortization	**41,193**	46,889
Capitalised in inventories	**(9,243)**	(7,474)
	31,950	39,415
Cost of inventories recognised as an expense		
— Cost of sales	**30,228**	31,464
— Research and development expenses	**10,328**	20,021

9. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operated.

The Company was incorporated in the Cayman Islands and is exempted from income tax.

No provision for Hong Kong Profits Tax has been made as the Group did not have any assessable income subjected to Hong Kong Profits Tax.

Entities in the State of Delaware are subject to Federal Tax at a rate of 21% and State of Delaware Profits Tax at a rate of 8.7%. Operations in the United States of America have incurred net accumulated operating losses for income tax purposes and no income tax provisions are recorded during the six months ended 30 June 2025 and 2024.

9. INCOME TAX EXPENSE (Continued)

Subsidiaries in Mainland China are subject to income tax at a rate of 25% pursuant to the Corporate Income Tax Law of the PRC and the respective regulations, with the exception of JW Therapeutics (Shanghai) Co., Ltd. (上海藥明巨諾生物科技有限公司) obtained its High-Tech Enterprise status in year of 2022 and hence is entitled to a preferential tax rate of 15% for a three-year period commencing the year of 2022.

No provision for Mainland China corporate income tax was provided for, as there's no assessable profit.

10. DIVIDENDS

No dividend was paid or proposed for the shareholders of the Company during the six months ended 30 June 2025 and 2024, nor has any dividend been proposed since the end of the reporting period.

11. LOSS PER SHARE

Basic loss per share

The calculation of the basic loss per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss attributable to the ordinary equity holders of the Company	**(267,265)**	(240,267)
	'000	*'000*
Weighted average number of ordinary shares in issue	**415,632**	413,083

Diluted loss per share

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the six months ended 30 June 2025 and 2024, the Company had one category of potential ordinary shares: the stock options granted to employees. As the Group incurred losses for the six months ended 30 June 2025 and 2024, the potential ordinary shares were not included in the calculation of diluted loss per share as their inclusion would be anti-dilutive. Accordingly, diluted loss per share for the six months ended 30 June 2025 and 2024 are the same as basic loss per share.

12. INTANGIBLE ASSETS

Relma-cel license

In December 2017, the Group entered into License and Strategic Alliance Agreement ("**Relma-cel License**") with Juno Therapeutics, Inc. ("**Juno**") to develop and commercialize Relma-cel in Mainland China, Hong Kong and Macau.

The upfront payment of USD11,570,000 (equivalent to RMB75,601,000) was initially recognised as intangible assets in 2017. The milestone payments amounted to USD5,000,000 (equivalent to RMB32,462,000) capitalised in 2021 as the completion of clinical treatment of 100 patients. Subsequently, the reimbursement payments of USD150,000 (equivalent to RMB1,045,000) in 2022 and USD1,400,000 (equivalent to RMB9,990,000) in 2024 further recognised as intangible assets for the upstream milestone payments by Juno as the achievement of clinical trial initiation milestones and the payment obligation became unconditional.

As at 30 June 2025, the carrying amount of the Relma-cel License amounted to RMB82,650,000 (31 December 2024: RMB89,490,000) (which is net of the accumulated amortisation of RMB47,063,000 (31 December 2024: RMB40,764,000)).

BCMA license

In April 2019, the Group entered into License Agreement — BCMA ("**BCMA License Agreement**") with Juno to develop and commercialize JWCAR129 in Mainland China, Hong Kong and Macau. The Group recognised the upfront payment amounted to USD9,140,000 (equivalent to RMB61,318,000) as intangible assets in year 2019.

Eureka licenses

In June 2020, the Group acquired the licenses in a business combination and recognised the licenses, which includes certain licenses under development and commercialization in Mainland China, Hong Kong, Macau, Taiwan and the member countries of Association of South East Asia Nation, at fair value on the acquisition date ("**Eureka Licenses**"). The Group recognised a total amount of USD95,300,000 (equivalent to RMB674,676,000) as intangible assets in year 2020.

2seventy license

In October 2022, the Group entered into the Collaboration Agreement with 2seventy bio, Inc. ("**2seventy**") for the development and commercialization of a cell therapy product directed to MAGE-A4 in Greater China. The Group provided 2seventy upfront payment in cash in an amount of USD3,000,000 (equivalent to RMB20,894,000) and recognised it as intangible assets.

As at 30 June 2025, BCMA license, Eureka licenses and 2seventy license with total carrying amount of RMB303,052,000 (31 December 2024: RMB458,855,000) were not yet ready for use.

12. INTANGIBLE ASSETS (Continued)

Impairment assessment

Intangible assets not yet ready for use are tested based on the recoverable amount of the cash-generating unit (CGU) to which the intangible asset is related. The appropriate cash-generating unit is at the pipeline level. The impairment test was performed for the pipeline by engaging an independent qualified professional valuer to estimate value in use as the recoverable amount of the pipeline. The value in use is estimated using discount cash flow approach.

With the assistance of an external appraiser, management determined the recoverable amount of the intangible assets not ready for use based on the following approach and the key assumptions:

- Cash inflows are generated for each pipeline based on the progress of clinical development and regulatory approval, commercial ramp up to reach expected peak revenue potential, and up to the end of the exclusivity for the product. The estimated revenue of each pipeline is based on the management's estimate of timing of commercialization. The costs and operating expenses are estimated as a percentage over the revenue forecast period based on the current margin levels of comparable companies with adjustments made to reflect the expected future price changes. The management considers the length of forecast period is appropriate because it generally takes longer for a biopharma company to generate positive cash flows, compared to companies in other industries, especially when the related products are under clinical trial. Hence, the management believes that a forecast period longer than five years is justifiable and consistent with industry practice. During the six months ended 30 June 2025, the range of forecast period was 10 to 15 years since 30 June 2025.

- The discount rate used is pre-tax and reflects the current market assessments of the time value of money and the risks specific to each of the cash-generating unit.

12. INTANGIBLE ASSETS (Continued)

Impairment assessment (Continued)

The key assumptions based on management's best estimates as adopted for the recoverable amount calculations are as follows:

	BCMA license	Eureka licenses	2seventy license
Pre-tax discount rate			
30 June 2025	**29.0%**	**28.6%**	**27.5%**
31 December 2024	28.9%	28.4%	27.3%
Revenue growth rate			
30 June 2025	**(2.0%)~40.4%**	**(2.0%)~229.4%**	**(18.6%)~108.6%**
31 December 2024	(2.0%)~40.4%	(2.0%)~229.4%	(18.6%)~108.6%
Gross margin			
30 June 2025	**61.0%~78.6%**	**86.2%~87.3%**	**47.6%~78.1%**
31 December 2024	72.8%~77.7%	75.9%~87.3%	57.6%~78.1%
Recoverable amount of CGU *(in RMB million)*			
30 June 2025	**54**	**231**	**60**
31 December 2024	51	386	49

Based on the result of above assessment, the Company made a provision for impairment of RMB14 million and RMB451 million on BCMA license and Eureka licenses as of 30 June 2025 (31 December 2024: RMB14 million and RMB299 million on BCMA license and Eureka licenses). The recoverable amount is significantly above the carrying amount of 2seventy license. Management believes that any reasonably possible change in any of these assumptions would not result in impairment.

13. PREPAYMENT FOR LICENSE

	As at 30 June 2025 *RMB'000* (Unaudited)	As at 31 December 2024 *RMB'000* (Audited)
Prepayment for license *(Note)*	**7,159**	7,189

Note: In January 2020, the Company entered into an Option and License Agreement with Acepodia Biotechnologies, Ltd. ("**Acepodia**"), pursuant to which, the Company was granted an exclusive option to acquire an exclusive right and license to manufacture, develop, use, sell, offer for sale, import and otherwise commercialize certain products. On 3 February 2020, the Company paid first instalment of USD1,000,000 to Acepodia.

14. OTHER NON-CURRENT ASSETS

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Rental deposits	**4,244**	4,512
Value-added tax recoverable	**1,535**	1,497
Prepayments for property, plant and equipment	**1,647**	1,647
	7,426	7,656

15. INVENTORIES

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Raw materials	**53,914**	25,106
Work in progress	**12,724**	6,151
Goods in transit	**383**	—
	67,021	31,257

16. TRADE RECEIVABLES

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Trade receivables from a related party *(Note 25)*	**25,055**	—
Less: allowance for credit losses	**—**	—
Trade receivables, net of allowance for credit losses	**25,055**	—

The Group allows an average credit period of 180 days to the related party.

16. TRADE RECEIVABLES (Continued)

The following is an analysis of trade receivables by age, presented based on the invoice date, which approximated the revenue recognition date.

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
0–60 days	**25,055**	—

17. OTHER RECEIVABLES AND PREPAYMENTS

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Prepayments to suppliers	**3,040**	1,786
Deposits	**157**	5,157
Others	**485**	290
	3,682	7,233

18. OTHER CURRENT ASSETS

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Value-added tax recoverable	**3,324**	9,950
Other	**1,083**	2,858
	4,407	12,808

19. TRADE AND OTHER PAYABLES

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Trade payables	**44,666**	2,116
Payables for purchase of services and R&D materials	**34,447**	38,029
Accrued expenses	**20,484**	20,086
Staff salaries and welfare payables	**4,084**	6,742
Value-added tax and payroll tax	**971**	2,908
Deferred income	**600**	600
	105,252	70,481

The average credit period on purchases of goods and services of the Group is 30–60 days.

The following is an aged analysis of trade payables, presented based on earlier of the date of goods and services received and the demand note at the end of each reporting period:

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
0–30 days	**4,669**	1,702
31–60 days	**1,023**	22
61–90 days	**30,500**	—
91–120 days	**8,185**	—
121–365 days	**82**	217
Over 365 days	**207**	175
	44,666	2,116

20. BORROWINGS

During the current interim period, the Group obtained new bank loans amounting to RMB74,368,000 (six months ended 30 June 2024: RMB135,000,000). The loans carry interest at fixed market rates of 2.5% to 3.0% and at variable market rates of 2.8% are repayable in instalments within a year. The proceeds were used to finance the operation of subsidiaries.

During the current interim period, in respect of a bank loan with a carrying amount of RMB74,500,000 as at 30 June 2025, the Group had breached certain of the terms of the bank loan in prior year, which were primarily related to the requirement of equity financing or profitability of the Company. On discovery of the breach, the directors of the Company informed the lender and commenced a renegotiation of the terms of the loan with the relevant lender. As at 30 June 2025, the negotiation had not been concluded. Since the lender has not agreed to waive its right to demand immediate payment as at the end of the reporting period, the loan has been classified as a current liability as at 30 June 2025.

Up to the date of approval for issuance of the condensed consolidated financial statements, the negotiation is still in progress. The directors of the Company are confident that their negotiation with the lender will ultimately reach a successful conclusion. In any event, should the lender call for immediate repayment of the loan, the directors of the Company believe that adequate alternative sources of finance are available to ensure that there is no threat to the continuing operations of the Group.

21. CONTRACT LIABILITIES

	As at 30 June 2025 *RMB'000* (Unaudited)	As at 31 December 2024 *RMB'000* (Audited)
Contract liabilities	**29,436**	16,207

As at 1 January 2024, the amount of contract liabilities was RMB30,424,000. Revenue recognised that was included in the contract liabilities balance at the beginning of the years during the six months ended 30 June 2025 and 2024 amounted to RMB16,207,000 and RMB30,424,000 respectively.

For the contracts which require prepayments from the customer, the Group typically receive all the amounts of the product once the order placed.

22. SHARE CAPITAL

Authorized:

	Number of ordinary shares *In thousands*	Nominal value of ordinary shares *USD*	RMB equivalent value *RMB'000*
At 1 January 2024, 30 June 2024, 1 January 2025 and 30 June 2025	5,000,000	50,000	332

Issued and fully paid:

	Number of ordinary shares *In thousands*	Nominal value of ordinary shares *USD*	RMB equivalent value *RMB'000*
At 1 January 2024 (audited)	412,396	4,124	27
Issuance of ordinary shares *(Note (a))*	1,468	15	*
Issuance of treasury shares hold in the trust *(Note (b))*	1,203	12	*
At 30 June 2024 (unaudited)	415,067	4,151	27

Issued and fully paid:

	Number of ordinary shares *In thousands*	Nominal value of ordinary shares *USD*	RMB equivalent value *RMB'000*
At 1 January 2025 (audited)	415,532	4,155	27
Issuance of ordinary shares *(Note (c))*	212	2	*
Issuance of treasury shares hold in the trust *(Note (d))*	488	5	*
At 30 June 2025 (unaudited)	416,232	4,162	27

* Amount is less than RMB1,000

22. SHARE CAPITAL (Continued)

Issued and fully paid: (Continued)

Notes:

(a) During the six months ended 30 June 2024, the Company issued a total of 1,468,433 ordinary shares to the Group's employees as the result of exercise of stock option after vesting period with a total exercise price of USD38,000 (equivalent to RMB268,000).

(b) On 2 April 2024, the Company issued and allotted 1,203,121 ordinary shares of USD0.01 each for the Pre-IPO Restricted Share Unit Scheme to Computershare Hong Kong Trustees Limited to hold on behalf of future participants of the Pre-IPO Restricted Share Unit Scheme.

(c) During the six months ended 30 June 2025, the Company issued a total of 211,994 ordinary shares to the Group's employees as the result of exercise of stock option after vesting period with a total exercise price of USD14,000 (equivalent to RMB102,000).

(d) On 21 March 2025, the Company issued and allotted 488,142 ordinary shares of USD0.01 each for the Pre-IPO Restricted Share Unit Scheme to Computershare Hong Kong Trustees Limited to hold on behalf of future participants of the Pre-IPO Restricted Share Unit Scheme.

23. RESERVES

	Share premium *RMB'000* *Note (a)*	Share-based compensation reserve *RMB'000* *Note (b)*	Treasury shares held in trust *RMB'000*	Foreign currency translation *RMB'000* *Note (c)*	Capital reserve *RMB'000* *Note (d)*	Total *RMB'000*
At 1 January 2024 (Audited)	6,080,788	356,530	(1)	199,602	12,226	6,649,145
Issuance of ordinary shares	268	—	—	—	—	268
Issuance of treasury share hold in the trust	—	—	*	—	—	*
Share-based compensation expenses	—	18,557	—	—	—	18,557
Currency translation differences	—	—	—	19,548	—	19,548
At 30 June 2024 (Unaudited)	6,081,056	375,087	(1)	219,150	12,226	6,687,518
At 1 January 2025 (Audited)	**6,081,191**	**393,839**	**(1)**	**237,841**	**12,226**	**6,725,096**
Issuance of ordinary shares	**102**	**—**	**—**	**—**	**—**	**102**
Issuance of treasury share hold in the trust	**—**	**—**	*	**—**	**—**	*
Share-based compensation expenses	**—**	**4,536**	**—**	**—**	**—**	**4,536**
Currency translation differences	**—**	**—**	**—**	**2,070**	**—**	**2,070**
At 30 June 2025 (Unaudited)	**6,081,293**	**398,375**	**(1)**	**239,911**	**12,226**	**6,731,804**

* Amount is less than RMB1,000

23. RESERVES (Continued)

Notes:

(a) Share premium arises from the issuance of the Company in excess of their par value.

(b) Share-based compensation reserve arises from share-based payment granted to employees of the Group.

(c) Foreign currency translation represents the difference arising from the translation of financial statements of companies within the Group that have a functional currency different from the presentation currency of RMB for the financial statements of the Group.

(d) Capital reserve represents the difference of aggregate consideration paid by the Group and the aggregate capital of the subsidiaries acquired before the year ended 31 December 2020.

24. SHARE-BASED PAYMENTS

Pre-IPO Incentivization Scheme and Restricted Share Unit Schemes

In order to attract, retain and motivate employees, directors and such other eligible persons and to provide a means of compensating them through the grant of options for their contribution to the growth and profits of the Group, and to allow such employees, directors and other persons to participate in the growth and profitability of the Group, the Company adopted the Pre-IPO Incentivization Scheme and Restricted Share Unit Schemes on 4 September 2019.

The Pre-IPO Incentivization Scheme and the Restricted Share Unit Schemes shall be valid and effective for a period of ten years commencing on the adoption date. All the options under the Pre-IPO Incentivization Scheme were granted between 4 September 2019 and 10 September 2020 (both days inclusive).

The maximum number of Shares in respect of which awards may be granted under the Pre-IPO Incentivization Scheme and the Restricted Share Unit Scheme shall not, in aggregate exceed 36,031,500 Shares which is a shared common pool.

There are two types of vesting schedule under the Pre-IPO Incentivization Scheme and the Restricted Share Unit Scheme: (i) with 30% will vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% will vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; and (ii) with 25% will vest on each anniversary of the vesting commencement date, respectively.

Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme

On 14 October 2020, the Company adopted the Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme to encourage participants to work towards enhancing the value of the Group and to reward their contribution to the Group.

The Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme will remain in force for a period of 10 years commencing on the date on which the Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme is adopted.

The maximum number of Shares in respect of which awards may be granted under the Post-IPO Restricted Share Unit Scheme shall not, in aggregate exceed 7,539,449 Shares and the maximum number of Shares in respect of which options may be granted under the Post-IPO Share Incentivization Scheme shall not in aggregate exceed 37,617,622 Shares.

24. SHARE-BASED PAYMENTS (Continued)

Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme (Continued)

There are two types of vesting schedule under the Post-IPO Share Option Scheme and the Restricted Share Unit Scheme granted before the year of 2025: (i) with 30% will vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% will vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively; and (ii) with 25% will vest on each anniversary of the vesting commencement date, respectively

Pursuant to a resolution dated 6 January 2025 ("**2025 January Plan**"), the Company granted 387,740 share options at a consideration of HKD1.36 per share and 77,548 restricted share units ("**RSUs**") at nil consideration to two employees of the Group as rewards for their services, full time devotion and professional expertise to certain of the Group's subsidiaries, subject to the meeting of the criteria of each employee's performance before the relevant vesting date under Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme.

Pursuant to a resolution dated 11 April 2025 ("**2025 April Plan**"), the Company granted 5,500,000 and 2,000,000 share options at a consideration of HKD1.48 per share to twelve employees and a director of the Group respectively as rewards for their services, full time devotion and professional expertise to certain of the Group's subsidiaries, subject to the meeting of the criteria of each employee's performance or other requirements before the relevant vesting date under Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme. In addition, the Company granted and vested on the date of grant 256,183 share options at a consideration of HKD1.48 per share to the director abovementioned as part of his remuneration package and recognition of his role with the Group and contribution to the development and growth of the Group for the preceding fiscal year.

Details of the share options/RSU granted on 6 January 2025 and 11 April 2025 are as follows:

Date of Grant	Grantee	Type	Vesting schedule defined in contract term	Number of share options/ RSU granted
6 January 2025	Two employees	Share option	Note 1	387,740
6 January 2025	Two employees	RSU	Note 1	77,548
11 April 2025	Twelve employees	Share option	Note 2	5,500,000
11 April 2025	A director	Share option	Note 3	2,000,000
11 April 2025	A director	Share option	Note 4	256,183

Note 1: The vesting schedules for 2025 January Plan share options and RSU is with 30% will vest on the second anniversary of the vesting commencement date and the remaining 30% and 40% will vest on the third anniversary and fourth anniversary of the vesting commencement date, respectively.

Note 2: The vesting schedules for 2025 April Plan share options granted to twelve employees is with 25% will vest on each anniversary of the vesting commencement date, respectively.

24. SHARE-BASED PAYMENTS (Continued)

Post-IPO Share Option Scheme and Post-IPO Restricted Share Unit Scheme (Continued)

Note 3: The vesting schedules for 2025 April Plan share options granted to a director is with relevant number of share options will vest six months from each of the respective dates upon the grantee's fulfillment of the respective performance targets. If the grantee fulfills a specific performance target (such fulfillment to be determined by the board in its sole discretion) on any date since the date of grant by 10 October 2034, all share options not previously vested pursuant to one or more of the respective performance targets will vest six months from the date on which such specific performance target has been fulfilled.

Note 4: The 256,183 share options for 2025 April Plan granted to a director was vested on the date of grant.

The following table summarizes the Group's share option activities:

	Number of share options
Outstanding as at 1 January 2025	10,165,053
Granted during the period	8,143,923
Forfeited during the period	(609,482)
Exercised during the period	(211,994)
Expired during the period	(1,431,732)
Outstanding as at 30 June 2025	16,055,768

In respect of the share options exercised during the period, the weighted average closing price of the Company's shares immediately before the dates on which the options were exercised was USD0.23.

In the current interim period, share options were granted on 6 January 2025 and 11 April 2025. The fair values of the options determined at the dates of grant were HKD0.94 and HKD0.87 to HKD1.00 respectively. The closing price of the Company's shares immediately before 6 January 2025 and 11 April 2025, the dates of grant, was HKD1.36 and HKD1.48 respectively.

The following assumptions were used to calculate the fair values of share options:

	6 January 2025	11 April 2025
Grant date option fair value per share	HKD0.94	HKD0.87–HKD1.00
Exercise price	HKD1.36	HKD1.48
Expected volatility	77.4%	78.7%
Risk-free interest rate	3.87%	3.33%

The Binomial model has been used to estimate the fair value of the options. The variables and assumptions used in computing the fair value of the share options are based on the best estimate. Changes in variables and assumptions may result in changes in the fair value of the options.

24. SHARE-BASED PAYMENTS (Continued)

The following table summarizes the Group's RSU activities:

	Number of RSUs
Outstanding as at 1 January 2025	2,885,980
Granted during the period	77,548
Forfeited during the period	(339,910)
Vested during the period	(178,059)
Outstanding as at 30 June 2025	2,445,559

At the end of each interim period, the Group revises its estimates of the number of options that are expected to vest ultimately. The impact of the revision of the estimates, if any, is recognised in profit and loss, with a corresponding adjustment to the share-based payments reserve.

25. RELATED PARTY TRANSACTIONS

(i) Other than as disclosed elsewhere in these condensed consolidated financial statements, the Group has following transactions and balances with the sole related party:

Name of related party	Relationship with the Group
Juno	Shareholder

Transactions with the related party

Grant of a non-exclusive license

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Juno	**25,107**	—

Purchase of materials — Viral vectors

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Juno	**38,633**	21,504

25. RELATED PARTY TRANSACTIONS (Continued)

(i) Other than as disclosed elsewhere in these condensed consolidated financial statements, the Group has following transactions and balances with the sole related party: (Continued)

Transactions with the related party (Continued)

Royalty fee

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Juno	**4,874**	5,209

Note: The Group is required to pay Juno royalty fee in cash for Relma-cel and any related diagnostic products based on annual net sales in the Territory, subject to certain adjustments in specified circumstances under the Relma-cel license.

Reimbursement

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Juno	**—**	9,978

Balances with the related party

Trade receivables

	As at 30 June 2025	As at 31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Juno	**25,055**	—

Trade and other payables

	As at 30 June 2025	As at 31 December 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Juno	**45,367**	4,818

Note: The balances due to Juno were unsecured, trade in nature and non-interest bearing.

25. RELATED PARTY TRANSACTIONS (Continued)

(ii) Compensation of key management personnel

The remuneration of the directors of the Company during the six months ended 30 June 2025 was as follows:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Directors' emoluments		
Fees, wages and salaries	**2,489**	2,889
Discretionary bonuses	**308**	—
Share-based compensation expenses	**560**	3,564
Other post-employment benefits	**37**	36
	3,394	6,489

26. EVENTS AFTER THE REPORTING PERIOD

There have been no significant events since the end of the Reporting Period.

In this report, unless the context otherwise requires, the following expressions have the meanings set out below. These expressions and their definitions may not correspond to any industry standard definitions, and may not be directly comparable to similarly titled expressions adopted by other companies operating in the same industries as our Company.

"associate(s)"	has the meaning ascribed to it under the Listing Rules
"Audit Committee"	the audit committee of the Board
"BCMA License Agreement"	the license agreement entered into between our Company and Juno dated April 11, 2019
"Board", "our Board" or "Board of Directors"	the board of Directors of our Company
"Business Development and Strategy Committee"	the business development and strategy committee of the Board
"CAR"	chimeric antigen receptor
"CAR-T"	chimeric antigen receptor T-cell
"CEO"	the chief executive officer of our Group
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"Chairman"	the chairman of the Board
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Company", "our Company", "the Company" or "JW Therapeutics"	JW (Cayman) Therapeutics Co. Ltd (Stock code: 2126), an exempted company with limited liability incorporated under the laws of the Cayman Islands on September 6, 2017, the shares of which are listed on the Main Board of the Hong Kong Stock Exchange
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"Consolidated Affiliated Entities"	the entities we control through the Contractual Arrangements, namely Shanghai Ju Ming and its subsidiaries Shanghai Ming Ju and Suzhou Ming Ju Biotechnology Co., Ltd. (蘇州明聚生物科技有限公司)
"Director(s)"	the director(s) of the Company
"Dr. Li"	Dr. Yiping James Li, our non-executive Director

"Frost & Sullivan"	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., a global market research and consulting company, which is an independent industry consultant
"Global Offering"	the Hong Kong public offering and the international offering of the Shares
"Group", "our Group", "the Group", "we", "us", or "our"	the Company, its subsidiaries and the Consolidated Affiliated Entities from time to time
"HKD" or "HK dollars"	Hong Kong Dollars, the lawful currency of Hong Kong
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC
"IFRS"	International Financial Reporting Standards
"IND"	investigational new drug or investigational new drug application, also known as clinical trial application in China
"Juno"	Juno Therapeutics, Inc., a company incorporated in Delaware, the United States on August 5, 2013 under its former name, FC Therapeutics, Inc., a wholly-owned subsidiary of Celgene which is in turn wholly-owned by BMS, and is one of our Substantial Shareholders
"License and Strategic Alliance Agreement"	the license and strategic alliance agreement entered into between our Company and Juno in December 2017
"Listing"	the listing of the Shares on the Main Board of the Hong Kong Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operates in parallel with the Growth Enterprise Market of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NDA"	new drug application
"Mr. Min Liu" or "Mr. Liu"	Mr. Min Liu, our executive Director, the Chairman and the CEO
"NMPA"	National Medical Products Administration of China (國家藥品監督管理局) and its predecessor, China Food and Drug Administration (國家食品藥品監督管理總局)

"Nomination Committee"	the nomination committee of the Board
"Post-IPO Incentivization Scheme"	the Post-IPO Share Option Scheme adopted by the Company on October 14, 2020
"Post-IPO Restricted Share Unit Scheme"	the Post-IPO Restricted Share Unit Scheme adopted by the Company on October 14, 2020
"Pre-IPO Incentivization Scheme"	the Pre-IPO Share Option Scheme adopted by the Company on September 4, 2019
"Prospectus"	the prospectus of the Company dated October 22, 2020
"R&D"	research and development
"Remuneration Committee"	the remuneration committee of the Board
"Reporting Period"	the six-month period from January 1, 2025 to June 30, 2025
"Restricted Share Unit Scheme"	the Pre-IPO Restricted Share Unit Scheme adopted by the Company on September 4, 2019
"Restricted Share Unit Schemes"	the Restricted Share Unit Scheme and the Post-IPO Restricted Share Unit Scheme
"RMB" or "Renminbi"	Renminbi, the lawful currency of China
"RSU(s)"	the restricted share unit(s) granted pursuant to the Restricted Share Unit Scheme
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Shanghai Ju Ming"	Shanghai Ju Ming Medical Technology Co., Ltd.* (上海炬明醫療技術有限公司), a limited liability company established under the laws of the PRC on July 10, 2017 and our Consolidated Affiliated Entity
"Share(s)"	ordinary share(s) in the capital of the Company with nominal value of USD0.00001 each
"Share Incentivization Schemes"	our Pre-IPO Incentivization Scheme, Restricted Share Unit Schemes and Post-IPO Incentivization Scheme
"Shareholder(s)"	holder(s) of Share(s)
"sNDA"	supplemental new drug application

"Stock Exchange" or "Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited
"subsidiary" or "subsidiaries"	has the meaning ascribed to it thereto in section 15 of the Companies Ordinance
"Substantial Shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"United States", "U.S." or "US"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US dollars", "U.S. dollars" or "USD"	United States dollars, the lawful currency of the United States
"%"	per cent

* *For identification purpose only*